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Malignant	  transformation	  is	  the	  process	  by	  which	  cells	  develop	  cancer	  properties.	  
While	  many	  causes	  for	  malignant	  transformation	  are	  known	  (i.e.	  common	  genetic	  
mutations	  and/or	  exposure	  to	  toxins	  or	  viruses),	  the	  basic	  requirements	  that	  allow	  
a	  cell	  to	  stay	  alive	  with	  altered	  nutrient	  and	  energy	  requirements	  are	  just	  now	  being	  
studied.	  In	  some	  tumor	  types	  malignant	  cells	  undergo	  changes	  that	  result	  in	  
metabolic	  differences	  compared	  to	  normal	  cells.	  These	  can	  include	  defects	  in	  
mitophagy	  resulting	  in	  an	  accumulation	  of	  dysfunctional	  mitochondria	  and/or	  a	  
metabolic	  switch	  resulting	  in	  increased	  glycolysis,	  termed	  the	  Warburg	  effect.	  
Increased	  tumor	  growth	  and	  metastasis	  have	  also	  been	  associated	  with	  
mitochondrial	  DNA	  mutations	  in	  some	  tumor	  types.	  In	  this	  study,	  we	  characterized	  
the	  mitochondrial	  function	  of	  malignant	  peripheral	  nerve	  sheath	  tumor	  (MPNST)	  
cell	  lines	  commonly	  used	  to	  study	  malignant	  transformation	  in	  Neurofibromatosis	  
Type	  I.	  We	  identified	  metabolic	  differences	  between	  NF1-­‐wildtype	  (STS26T)	  and	  
NF1-­‐deficient	  (ST88-­‐14,	  90-­‐8,	  and	  S462)	  MPNST	  cell	  lines	  by	  measuring	  
extracellular	  acidification	  and	  oxygen	  consumption,	  mitochondrial	  respiration	  
protein	  expression,	  and	  ROS	  levels.	  	  Similar	  to	  findings	  from	  other	  malignant	  
tumors,	  all	  MPNST	  cell	  lines	  were	  more	  glycolytic	  compared	  to	  non-­‐tumorigenic	  
	  iv	  
normal	  human	  Schwann	  cells	  and	  surprisingly	  NF1-­‐deficiency	  correlated	  with	  lower	  
glycolytic	  and	  mitochondrial	  respiratory	  rate	  compared	  to	  wildtype	  MPNST.	  
Mitochondrial	  respiratory	  rates	  and	  respiratory	  protein	  expression	  were	  
significantly	  lower	  in	  the	  NF1-­‐deficient	  MPNST	  cell	  lines	  when	  compared	  to	  NF1-­‐
wildtype	  MPNST	  cells.	  These	  findings	  demonstrate	  that	  neurofibromin	  affects	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NF1	  AND	  MALIGNANT	  PERIPHERAL	  NERVE	  SHEATH	  TUMORS	  
Malignant	   peripheral	   nerve	   sheath	   tumors	   (MPNST)	   are	   highly	   aggressive,	  
invasive	   sarcomas	   of	   the	   connective	   tissue	   that	   surrounds	   peripheral	   nerves.	  
MPNST	   account	   for	   nearly	   10%	   of	   all	   soft	   tissue	   sarcomas	   (Doorn	   et	   al.,	   1995,	  
Grobmyer	   et	   al.,	   2008)	   and	   typically	   present	   as	   a	   painful,	   rapidly	   enlarging	  mass,	  
often	   diagnosed	   at	   an	   advanced	   stage	   with	   distant	   metastases	   that	   have	   a	   poor	  
prognosis	  (Anghileri	  et	  al.,	  2006;	  Ferner	  and	  Gutmann,	  2002).	  There	  is	  a	  low	  rate	  of	  
sporadic	   MPNST	   development	   in	   the	   general	   population	   (0.001%)	   (Ferner	   and	  
Gutmann,	   2002;	  Ducatman	   et	   al.,	   1986);	   however,	   the	   lifetime	   risk	   is	   8	   to	   13%	   in	  
patients	  with	  Neurofibromatosis	  Type	  1	   (NF1)	   (Evans	  et	  al.,	  2002).	   In	   fact,	   almost	  
half	  of	  all	  MPNST	  are	  diagnosed	   in	  NF1	  patients.	  NF1	   is	  also	  an	   indicator	   for	  poor	  
prognosis,	  suggesting	  that	  NF1	  loss	  in	  MPNST	  may	  augment	  the	  potential	  detriment	  
of	  this	  tumor	  type	  to	  human	  life	  (Porter	  et	  al.,	  2009).	  	  
Neurofibromatosis	   type	   1	   or	   von	   Recklinghausen	   disease	   is	   an	   autosomal	  
dominant	  disease	  that	  occurs	  in	  approximately	  1/3000	  live	  births	  (Friedman	  1999).	  	  
NF1	  is	  associated	  with	  defective	  functionality	  or	  mutations	  in	  the	  NF1	  gene,	  which	  
can	  occur	   sporadically	  or	  be	   inherited	   (Riccardi	  2010;	  Staser	  et	   al.,	   2010;	   Jett	   and	  
Friedman	  2010;	  Parrinello	  and	  Lloyd	  2009;	  McClatchey	  2007).	  Located	  at	  17q11.2,	  
NF1	  is	  a	  large,	  highly	  mutated	  gene,	  encompassing	  more	  than	  350	  kb	  and	  containing	  
61	   exons	   (Ledbetter	   et	   al.,	   1989;	   Cawthon	   et	   al.,	   1990;	   Marchuk	   et	   al.,	   1991).	  
Pathological	  mutations	  are	  found	  across	  the	  entire	  NF1	  gene	  and	  range	  from	  single	  
nucleotide	  substitutions	  to	  large	  deletions	  (Zenker	  2011).	  
	  3	  
NF1	   belongs	   to	   a	   class	   of	   developmental	   disorders	   commonly	   called	  
“RASopathies”.	   	   These	   disorders	   are	   caused	   by	   germline	   mutations	   in	   genes	   that	  
encode	   protein	   component(s)	   of	   the	   Ras/MAPK	   pathway	   family	   (Zenker	   2011;	  
Tidyman	  et	  al.	  2009).	  Neurofibromin	   is	   a	  GTPase	  activating	  protein	   that	   increases	  
the	   rate	   of	   Ras-­‐GTP	   hydrolysis,	   converting	   active	   Ras-­‐GTP	   to	   inactive	   Ras-­‐GDP	  	  
(Ballester	  et	  al.,	  1990;	  Martin	  et	  al.,	  1990;	  Xu	  et	  al.,	  1990).	  Ras	  is	  a	  membrane	  bound	  
G-­‐protein	   involved	   in	   the	   activation	   of	   MAPK/ERK	   pathway.	   The	   MAPK/ERK	  
pathway	   plays	   a	   critical	   role	   in	   cell	   proliferation,	   growth,	   and	   differentiation.	  
Therefore,	   loss	   of	   neurofibromin,	   a	   ubiquitously	   expressed	   protein,	   will	   cause	   an	  
aberrant	   increase	   in	   Ras	   signaling	   that	   results	   in	   a	   multiplicity	   of	   observed	  
manifestations	   with	   varying	   degrees	   of	   severity.	   Figure	   1	   shows	   the	   MAPK/ERK	  
signal	   transduction	   pathway.	   NF1	   patients	   are	   susceptible	   to	   learning	   deficits,	  
psychiatric	  disorders	  and	  cognitive	  dysfunctions,	  bone	  and	  skeletal	  malformations,	  
and	   vascular	   problems	   in	   addition	   to	   the	   development	   of	   tumors	   (Thomas	   et	   al.	  
2006;	   Shilyansky	   et	   al.,	   2010;	  Hyman	   et	   al.,	   2006;	   Rosser	   et	   al.,	   2003;	   Krab	   et	   al.,	  
2008;	  Lee	  and	  Stephenson	  2007).	  	  
Although	   individuals	   with	   NF1	   are	   prone	   to	   developing	   other	   cancers,	  
including	   optic	   glioma,	   leukemia,	   and	   juvenile	   myelomonocytic	   leukemia	   (JMML),	  
the	   most	   common	   neoplasm	   in	   individuals	   with	   NF1	   are	   benign	   nerve	   sheath	  
tumors	  of	  the	  peripheral	  nervous	  system,	  called	  neurofibromas.	  Neurofibromas	  are	  
present	  in	  >99%	  of	  NF1	  patients	  (Ferner	  et	  al.,	  2006).	  Neurofibromas	  are	  thought	  to	  
originate	   from	   nonmyelinating	   Schwann	   cells	   but	   contain	   other	   cell	   types	   like	  
fibroblasts	   and	   mast	   cells	   (Zheng	   et	   al.,	   2008,	   Serra	   et	   al.,	   2000).	   The	   dermal	   or	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subcutaneous	   type	   can	   be	   disfiguring,	   painful,	   and	   sensitive	   to	   touch	   but	   are	   not	  
known	   to	   become	   malignant.	   Plexiform	   neurofibromas	   are	   large,	   slow	   growing,	  
diffuse	   neoplasms	  with	   a	   propensity	   to	   enwrap	   structures	  within	   the	   body,	   often	  
involving	   multiple	   nerve	   fascicles,	   nerve	   branches,	   and	   blood	   vessels.	   As	   with	  
dermal	  neurofibromas,	   the	  plexiform	   type	  can	  be	  disfiguring	  and	  painful,	  but	  may	  
additionally	   lead	  to	   loss	  of	  sensation	  and	  weakness	  (Korf	  1999).	  Both	  tumor	  types	  
can	  be	  asymptomatic.	  	  
Plexiform	   neurofibromas	   are	   found	   in	   50%	   of	   NF1	   patients	   and	   have	   the	  
potential	  to	  become	  a	  malignant	  peripheral	  nerve	  sheath	  tumor	  (MPNST)	  (Tonsgard	  
et	  al.,	  1998).	  The	  five-­‐year	  survival	  rate	  for	  an	  NF1	  patient	  with	  a	  MPNST	  was	  half	  
that	   of	   patients	   with	   a	   sporadic	   MPNST	   (21%)	   from	   the	   date	   of	   diagnosis	   –	  
indicating	  that	  loss	  of	  the	  NF1	  protein	  may	  play	  a	  role	  in	  the	  aggressiveness	  of	  these	  
tumors	   (Evans	   et	   al.,	   2002).	   The	   increased	   incidence	   of	   MPNST	   in	   the	   NF1	  
population	  contributes	  to	  a	  higher	  mortality	  rate,	  with	  the	  average	  age	  of	  death	  for	  
NF1	  patients	  being	  54.4	  years,	  15.6	  years	  lower	  than	  the	  70.1	  years	  for	  the	  general	  
population	   at	   the	   time	   of	   the	   study	   (Rasmussen	   et	   al.,	   2001).	   However,	   a	   more	  
recent	  meta-­‐analysis	   of	  MPNST	  outcomes	   found	  no	   significant	   difference	   between	  
patients	  with	  or	  without	  a	  diagnosis	  of	  NF1.	  These	  findings	  could	  be	  confounded	  as	  
NF1	  mutation	   or	   loss	  may	   be	   implicated	   in	   some	   sporadic	  MPNST	   (Kolberg	   et	   al.,	  
2013).	  Neurofibromatosis	  Type	  I	  cannot	  be	  cured	  and	  current	  therapies	  treat	  only	  
symptoms	   and	   complications.	   Surgical	   resection	   is	   the	   treatment	   option	   of	   choice	  
due	   to	   a	   lack	   of	   effective	   chemotherapies	   for	   MPNST.	   MPNST	   resection	   involves	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functional	   loss	  of	   a	  nerve(s)	   that	   can	  have	   severe	  health	   complications	   contingent	  























FIGURE	  1	  	  
Depiction	  of	  the	  Ras	  activated	  ERK/MAPK	  pathway.	  	  
Activation	   of	   Ras	   through	   the	   Ras-­‐Raf-­‐MEK-­‐ERK	   pathway	   results	   in	   increased	  
cellular	  proliferation,	  survival,	  and	  transformation.	  TRK	  =	  Tyrosine	  receptor	  kinase,	  





























CANCER	  AND	  METABOLISM	  
Malignant	   transformation	   is	   the	   process	   by	   which	   cells	   acquire	   cancer	  
properties	  and	  may	  occur	  in	  primary	  tissues	  or	  as	  a	  secondary	  transformation	  from	  
a	   benign	   state.	   Malignant	   cells	   have	   accumulated	   genetic	   mutations	   that	  
fundamentally	  alter	  cellular	  behavior.	  Some	  properties	  of	  cancer	  are:	  growth	  in	  the	  
absence	   of	   growth	   factors,	   lack	   of	   contact	   inhibition,	   resistance	   to	   apoptosis	   and	  
senescence,	   persistent	   telomerase	   activity,	   rapid	   growth,	   tissue	   invasion	   and	  
metastases,	   clonal	   nature,	   and	   angiogenesis.	   Common	   genetic	   mutations,	   toxin	  
exposure,	  and	  viruses	  are	  a	  few	  of	  the	  many	  known	  mutagens	  that	  cause	  malignant	  
transformation.	  	  Metabolic	  changes	  also	  occur	  in	  malignant	  cells	  in	  response	  to	  the	  
altered	  cellular	  behavior	  (Zhang	  and	  Yang,	  2013).	  	  
Two	  of	  the	  major	  energy	  production	  pathways	  within	  cells	  are	  glycolysis	  and	  
oxidative	   phosphorylation.	   Glycolysis	   is	   a	   serial	   process	   that	   consists	   of	   ten	  
enzymatically	   catalyzed	   chemical	   reactions	   within	   the	   cytoplasm	   resulting	   in	   the	  
degradation	   of	   glucose	   to	   pyruvate.	   ATP	   and	   electrons	   are	   produced	   as	   a	  
consequence	  of	  glycolysis	  (Hill	  et	  al.,	  2012).	  Many	  of	  the	  intermediates	  generated	  in	  
glycolysis	   serve	  as	  precursors	   in	  other	  biosynthetic	  pathways.	  The	  end	  product	  of	  
glycolysis,	   pyruvate,	   is	   a	   regulatory	  modifier	   in	  multiple	  metabolic	   processes.	   For	  
example,	  under	  normal	  oxygen	  conditions	  pyruvate	  can	  be	  funneled	  in	  the	  citric	  acid	  
cycle,	   fermented	   to	   lactic	   acid	   in	   anoxic	   environments,	   and	   can	   also	   serve	   as	   a	  
precursor	  for	  fatty	  acids	  and	  carbohydrates.	  	  
Increased	  glycolysis	  is	  often	  observed	  in	  cancer	  cells.	  This	  phenomenon	  has	  
been	  well	  studied	  and	   is	  called	  the	  Warburg	  effect	  (Warburg,	  1956).	  The	  Warburg	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effect	   results	   in	   a	   glycolytic	   shift	   such	   that	   glucose	   consumption	   is	   increased.	  
Because	   glucose	   consumption	   can	   be	   visualized	   and	   measured	   using	  
fluorodeoxyglucose	  (FDG)	  positron	  emission	  tomography	  (PET),	  this	  technology	  is	  a	  
common	  radiopharmaceutical	  imaging	  technique	  used	  in	  cancer	  diagnosis.	  Possible	  
explanations	   for	   the	  Warburg	   effect	   (i.e.	   increased	   cellular	   glycolysis)	   include:	   1)	  
increased	  glycolytic	  biosynthetic	  precursor	  production	  necessary	  for	  tumor	  growth,	  
2)	  glycolysis	  can	  produce	  ATP	  at	  a	  faster	  rate	  than	  oxidative	  phosphorylation,	  and	  3)	  
a	   hypoxic	   microenvironment	   that	   will	   reduce	   cellular	   oxidative	   phosphorylation	  
capabilities	  (Nakajima	  and	  van	  Houten,	  2013).	  	  	  
Cancer	  cells	   construct	  more	  cellular	   components	   than	  normal	   cells	  because	  
of	  increased	  proliferation.	  Pyruvate	  is	  used	  as	  a	  precursor	  for	  the	  synthesis	  of	  other	  
molecules	   like	   fatty	   acids,	   cholesterol,	   and	   glucose	   that	   are	   involved	   in	   the	  
construction	  of	  cellular	  components.	  Pyruvate	  can	  also	  feed	  into	  the	  citric	  acid	  cycle	  
and	   pentose	   phosphate	   pathway,	   which	   in	   turn	   have	   intermediates	   that	   are	  
precursors	   for	  amino	  acids,	  nucleotides,	  and	  tetrapyrroles	  (like	  the	  heme	  group	   in	  
hemoglobin).	  Increased	  biosynthetic	  precursor	  production	  is	  essential	  for	  increased	  
proliferation.	   Glycolysis	   is	   faster	   at	   producing	   energy	   than	   oxidative	  
phosphorylation	  so	  rapidly	  dividing	  cells	  may	  utilize	  glycolysis	  more	  than	  oxidative	  
phosphorylation	   because	   it	   can	   maintain	   pace	   with	   proliferation.	   Many	   tumors	  
outgrow	  an	  adequate	  blood	  supply.	  Without	  sufficient	  blood	  perfusion,	   the	  oxygen	  
supply	   is	   low,	   creating	   a	   hypoxic	  microenvironment.	  Many	   tumors	   are	   capable	   of	  
increasing	  glycolysis	  to	  overcome	  this	  deprivation	  (Gillies	  et	  al.,	  2008).	  This	   forces	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tumor	  cells	  to	  produce	  energy	  by	  anaerobic	  glycolysis	  as	  the	  capability	  of	  oxidative	  
phosphorylation	  is	  diminished.	  	  
Oxidative	   phosphorylation,	   the	   other	  major	   energy	   production	   pathway,	   is	  
far	   more	   efficient	   at	   ATP	   production	   than	   glycolysis.	   This	   process	   occurs	   in	  
mitochondria.	  Mitochondria	   are	   often	   called	   the	   “powerhouse	   of	   the	   cell”	   as	   they	  
produce	   most	   of	   the	   cell’s	   energy.	   	   Oxidative	   phosphorylation	   utilizes	   electrons	  
produced	  in	  glycolysis	  and	  the	  citric	  acid	  cycle	  to	  create	  a	  proton	  gradient	  across	  the	  
inner-­‐membrane	  of	  mitochondria	  (Hill	  et	  al.,	  2012).	  Protons	  are	  pumped	  out	  of	  the	  
matrix	   and	   into	   the	   inter-­‐membrane	   space	   by	   specialized	   proteins	   using	   the	  
movement	   of	   electrons	   down	   the	   electron	   transport	   chain	   as	   energy.	   	   Electrons	  
travel	   the	   transport	   chain	   towards	   increasing	   (higher)	   standard	   reduction	  
potentials	   before	   reducing	   O2	   and	   forming	   water.	   The	   electrochemical	   proton	  
gradient	  is	  used	  to	  power	  the	  production	  of	  ATP	  using	  ATP	  synthase	  (Complex	  V).	  In	  
this	   process,	   protons	   follow	   their	   electrochemical	   gradient	   from	   the	   inter-­‐
membrane	   space	   into	   the	   matrix	   through	   ATP	   synthase.	   ATP	   synthase	   then	  
mechanically	   forces	   ADP	   and	   Pi	   together	   producing	   ATP.	   Peter	   Mitchell	   first	  
suggested	  the	  chemiosmotic	  theory	  of	  energy	  production	  in	  1961	  (Mitchell,	  1961).	  
Figure	   2	   is	   an	   illustration	   of	   the	   electron	   transport	   chain	   and	   oxidative	  
phosphorylation.	  	  
Mitochondria	  have	  an	  important	  role	  in	  normal	  cellular	  homeostasis.	  Besides	  
producing	   energy	   through	   oxidative	   phosphorylation,	   mitochondria	   also	   play	   an	  
integral	   role	   in	   calcium	   storage	   and	   signaling,	   membrane	   potential	   regulation,	  
apoptosis,	   steroid	   synthesis,	   and	   hormonal	   signaling.	   During	   malignant	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transformation,	   mutations	   in	   the	   mitochondrial	   and	   nuclear	   DNA	   that	   influence	  
these	   processes	   contribute	   to	   altered	   mitochondrial	   metabolism	   and	   signaling;	  
however,	   the	   impact	   these	   changed	   mitochondria	   have	   on	   cells	   remains	   unclear.	  
Recent	  evidence	  has	  demonstrated	  that	  some	  changes	  in	  the	  pathways	  that	  regulate	  






































Electron	  Transport	  Chain	  and	  Oxidative	  Phosphorylation	  
A	  depiction	  of	  the	  Chemiosmotic	  theory	  of	  energy	  production	  within	  mitochondria	  
with	  the	  ETC	  and	  ATP	  synthase.	  ETC	  =	  electron	  transport	  chain,	  Complex	  I	  =	  NADH	  
dehydrogenase,	  NADH	  =	  nicotimamide	  adenine	  dinucleotide,	  Complex	  II	  =	  succinate	  
dehydrogenase,	   Q	   =	   coenzyme	   Q,	   Complex	   III	   =	   coenzyme	   Q-­‐cytochrome	   C	  
reductase,	  Cyto	  C	  =	  cytochrome	  C,	  Complex	  IV	  =	  cytochrome	  C	  oxidase,	  Complex	  V	  =	  



































ROS,	  MITOCHONDRIA,	  AND	  CANCER	  
A	   consequence	   of	   oxidative	   phosphorylation	   is	   the	   production	   of	   reactive	  
oxygen	   species	   (ROS).	   	   ROS	   are	   a	   chemically	   reactive	   family	   of	   oxygen	   containing	  
molecules	   that	   are	   involved	   in	   cellular	   signaling	   and	   the	   pathogen	   immune	  
response.	  ROS	  like	  superoxides,	  peroxides,	  and	  hydroxyl	  radicals	  can	  cause	  cellular	  
damage	   if	   allowed	   to	   accumulate	   –	   i.e.	   too	  much	   is	   being	  produced	  or	   too	   little	   is	  
being	   neutralized.	   ROS	   can	   damage	   lipids,	   DNA,	   RNA,	   enzyme	   co-­‐factors,	   and	  
proteins	  by	  changing	  their	  chemical	  structure.	  The	  term,	  oxidative	  stress,	  describes	  
the	   imbalance	   between	   the	   production	   of	   ROS	   and	   the	   cellular	   capability	   to	  
neutralize	  it.	  Mitochondria	  are	  the	  largest	  producers	  of	  ROS	  in	  a	  cell.	  Increased	  ROS	  
production	  is	  observed	  in	  tumor	  cells	  and	  is	  thought	  to	  contribute	  to	  tumorigenesis	  
(Szatrowski	  et	  al.,	  1993).	  ROS	  are	  also	  known	  to	  regulate	  mitophagy	  and	  play	  a	  role	  
in	   the	   glycolytic	   switch	   associated	   with	   the	  Warburg	   effect	   (Zhu	   et	   al.,	   2013	   and	  
Chen	  et	  al.,	  2015).	  
	   Autophagy	  or	  “self-­‐eating”	  is	  the	  degradation	  of	  dysfunctional	  or	  unnecessary	  
cellular	   components.	   The	   building	   blocks	   that	   make	   up	   the	   degraded	   cellular	  
components	   may	   be	   recycled	   and	   used	   to	   build	   a	   different	   structure	   (Hill	   et	   al.,	  
2012).	   A	   cell	   may	   use	   autophagy	   to	   maintain	   energy	   levels	   during	   starvation	   by	  
deriving	   energy	   from	   the	  breakdown	  of	   cellular	   components.	  Autophagy	  has	  been	  
well	  researched	  in	  cancer	  and	  the	  process	  has	  been	  shown	  to	  have	  both	  anti-­‐tumor	  
and	   tumor	   promoting	   capabilities	   for	   a	   cell	   (Boland	   et	   al.,	   2013).	   For	   example,	  
autophagy	  can	  suppress	  cancer	  development	   through	   the	  degradation	  of	  damaged	  
organelles	   and	   other	   cellular	   components,	   preventing	   the	   promotion	   of	   abnormal	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proliferation	   and/or	   signaling.	   Alternatively,	   autophagy	   can	   promote	   tumor	   cell	  
growth	  and	  survival	  by	  allowing	  the	  cell	   to	  compensate	   for	  metabolic	  stressors	  by	  
using	  cellular	  components	  as	  an	  energy	  source.	  Metabolic	  stressors	  include:	  nutrient	  
deprivation	   and	   excess,	   hypoxia,	   and	  oncogene	   activation	   (Wellen	   and	  Thompson,	  
2010).	  
Mitophagy	  is	  a	  mitochondria	  specific	  form	  of	  autophagy	  that	  is	  important	  in	  
maintaining	   the	  appropriate	   amount	  of	  mitochondria	   in	   a	   cell.	   Every	   cell	   type	  has	  
distinct	   energy	   requirements	   for	   optimal	   health	   and	   function.	   Therefore,	  
mitochondrial	   content	   is	   a	   critical	   indicator	   for	   cell	   health.	   The	   amount	   of	  
mitochondria	   within	   a	   cell	   is	   a	   tightly	   regulated	   balance	   between	   two	   processes:	  
biogenesis	  and	  mitophagy.	   If	   the	  balance	   is	  disrupted	  resulting	   in	   too	  much	  or	   too	  
little	   mitochondria	   then	   intracellular	   signaling	   and	   energy	   production	   can	   be	  
thrown	  into	  disarray	  (Boland	  et	  al.,	  2013).	  Mitochondria	  are	   the	  major	  site	  of	  ROS	  
production	  and	  are	  sensitive	  to	  oxidative	  damage.	  Damaged	  mitochondria	  may	  not	  
produce	   ATP	   efficiently	   and	   may	   produce	   more	   ROS	   than	   healthy	   mitochondria,	  
perturbing	   the	   balance	   between	   normal	   ROS	   production	   and	   ROS	   elimination.	  
Mitophagy	   is	   a	   selective	   process	   that	   occurs	   to	   both	   healthy	   and	   damaged	  
mitochondria.	  Mitophagy	  helps	  prevent	  the	  build-­‐up	  of	  damaged	  mitochondria	  (Zhu	  
et	  al.,	  2013).	  	  	  
Like	   autophagy,	   increased	   mitophagy	   has	   been	   observed	   in	   some	   cancers	  
(Boland	   et	   al.,	   2013).	   Mitochondria	   increase	   ROS	   production	   in	   response	   to	  
metabolic	   stress.	   Cells	   use	   mitochondrial	   ROS	   as	   an	   indicator	   of	   mitochondrial	  
health	   (Wellen	   and	   Thompson,	   2010).	   Moderate	   increases	   in	   ROS	   signal	   for	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increased	  mitophagy	  as	  cellular	  function	  might	  be	  salvageable	  by	  elimination	  of	  the	  
damaged	  mitochondria,	  while	  excessive	  increases	  in	  ROS	  signal	  apoptosis	  due	  to	  the	  
probability	   of	   extensive	   systematic	   mitochondrial	   damage	   (Frank	   et	   al.,	   2012).	  
Therefore,	   it	   makes	   sense	   that	   tumor	   cells	   would	   have	   an	   increase	   in	   ROS	   and	  
mitophagy	   after	   episodes	   of	   oncogene	   activation,	   acidic	   or	   hypoxic	   tumor	  
microenvironments	   and	   nutrient	   depletion.	   The	   increased	   glycolysis	   commonly	  
found	   in	   tumors	  can	  result	   in	  an	  acidic	   tumor	  microenvironment,	  which	   is	  able	   to	  
increase	  mitophagy	   through	  metabolic	   stress	   pathways.	   The	   same	   applies	   for	   the	  
nutrient	   depletion	   that	   can	   occur	   when	   a	   tumor	   grows	   beyond	   the	   nutrient	  
capability	  of	   its	   vascular	   supply.	  When	  a	   cell	   is	  not	  meeting	   its	   increased	  nutrient	  
demands,	   it	   can	   start	   to	   degrade	   cellular	   components,	   including	   mitochondria.	  
Growth	   beyond	   the	   vascular	   supply	   can	   also	   cause	   tissue	   hypoxia.	   Hypoxia	   can	  
induce	   oxidative	   stress	   and	   promote	   mitophagy	   because	   not	   enough	   oxygen	   is	  
present	  for	  proper	  mitochondrial	  respiration.	  The	  increased	  mitophagy/autophagy	  
observed	   in	   some	   cancer	   cells	   lead	   to	   resistance	   to	   several	   classes	   of	  










Since	   the	  Ras/MAPK	  pathway	   family	  of	  proteins	  are	  known	   to	   regulate	  cell	  
growth,	   and	   cellular	   proliferation	   necessitates	   specific	   energy	   requirements,	   it	   is	  
particularly	   interesting	  to	  the	  NF1	  tumorigenesis	   field	  that	  Ras	  and	  neurofibromin	  
have	  been	  found	  to	  be	  localized	  in	  mitochondria	  (Roudebush	  et	  al.,	  1997,	  Amigoni	  et	  
al.,	   2013).	   	   The	   purpose	   of	   NF1	   and	   Ras	   in	   mitochondrial	   regulation	   is	   currently	  
unknown.	   However,	   the	   probability	   that	  NF1	   loss	   in	   MPNST	   perpetuates	   a	   more	  
aggressive	  tumor	  as	  NF1	  patients	  with	  MPNST	  die	  at	  a	  faster	  rate	  than	  the	  general	  
population,	   suggests	   that	   these	   pathways	   may	   play	   a	   role	   in	   the	   energy	  
requirements	   necessary	   for	   tumor	   growth	  or	   transformation.	  Mitochondria	   play	   a	  
vital	   role	   in	   balancing	  both	   energy	   regulation	   and	   a	   cell’s	   response	   to	   stress	   –	   i.e.	  
cellular	   life	   or	   death	   decisions.	   However,	   NF1-­‐status	   dependent	   metabolic	  
differences	  in	  malignant	  peripheral	  nerve	  sheath	  tumors	  have	  never	  been	  reported.	  
Therefore,	   previous	   findings	   showing	   ROS-­‐associated	   behavioral	   deficits	   with	  
correlated	  mitochondria	   morphology	   alterations	   in	   murine	  models	   of	  Nf1	   loss	   or	  
Ras	   hyperactivation,	   suggests	   that	   Nf1/Ras	   signaling	   pathway	   may	   influence	  
mitochondrial	  heath	  and	  mitochondrial	  respiration	  (Mayes	  et	  al.,	  2013).	  
While	  metabolic	  changes	  in	  NF1	  or	  MPNST	  have	  not	  been	  demonstrated,	  the	  
effect	  of	  oncogenic	  Ras	  hyperactivation	  on	  metabolism	  has	  been	  studied.	  Increased	  
glycolytic	   rates	   have	   been	   reported	   in	   hyperactive	  Ras	   or	  Ras	   transformed	   tumor	  
cells,	   which	   is	   consistent	   with	   Warburg	   effect	   observations	   in	   many	   cancers	   (de	  
Groof	  et	  al.,	  2009;	  Hu,	  Lu	  and	  Chen	  et	  al.,	  2012;	  Telang	  et	  al.,	  2006).	  	  However,	  data	  
regarding	   the	   effect	   of	   Ras	   hyperactivation/transformation	   on	   mitochondrial	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respiration	  is	  less	  consistent	  as	  both	  increases	  and	  decreases	  have	  been	  reported.	  A	  
more	   recent	   report	   claimed	   that	   an	   increase	   in	   mitochondrial	   respiration	   during	  
transformation	  precedes	  an	  ultimate	  decrease	  in	  the	  transformed	  cells	  (de	  Groof	  et	  
al.,	   2009).	   Moreover,	   Ras	   transformed	   cells	   experience	   an	   “autophagy	   addiction”,	  
meaning	   that	   the	   transformed	   cells	   have	   increased	   autophagy	   that	   is	   required	   for	  
tumorigenesis	   and	   to	   maintain	   some	   energy	   production	   via	   oxidative	  
phosphorylation	   by	   ensuring	   a	   pool	   of	   healthy	  mitochondria	   (Guo,	   Chen,	  Mathew,	  
and	  Fan	  et	  al.,	  2011).	  	  
MPNST	  cell	   lines	  have	  been	  used	  extensively	   throughout	   the	  years	  as	  an	   in	  
vitro	   model	   for	   NF1.	   The	   goal	   of	   this	   study	  was	   to	   determine	  whether	  metabolic	  
differences	   exist	   between	  MPNST	   cell	   lines	   and	   if	   neurofibromin	  plays	   a	   role.	  The	  
MPNST	   cell	   lines	   in	   this	   study	   are	   primary	   cell	   lines	   derived	   from	   MPNST	   that	  
occurred	  in	  patients.	  One	  cell	  line	  was	  derived	  from	  a	  cancer	  patient	  with	  no	  history	  
or	   presentation	   of	   NF1	   (STS26T)	   while	   the	   other	   three	   MPNST	   cell	   lines	   were	  
derived	  from	  MPNST	  in	  NF1	  patients	  (ST88-­‐14,	  90-­‐8,	  and	  S462).	  The	  tumor	  lines	  are	  
compared	   to	   each	   other	   and	   to	   normal	   human	   Schwann	   cells	   (NHSC).	  MPNST	   are	  
thought	   to	   be	   tumors	   derived	   from	   a	   Schwann	   cell	   lineage	   but	   it	   has	   not	   been	  
proven;	   therefore,	   these	   cells	   are	   probably	   the	  most	   appropriate	   non-­‐tumorigenic	  
control	   cell	   line	   at	   this	   time.	   We	   demonstrate	   for	   the	   first	   time	   that	   NF1	   status	  
significantly	   affects	   the	   metabolic	   profiles	   of	   MPNST.	   NF1	   status	   correlates	   with	  
differences	   in	  glycolysis	  and	  mitochondrial	   respiratory	  metabolic	  profiles	  and	   that	  
the	   disparities	   in	   mitochondrial	   respiration	   might	   be	   partially	   attributable	   to	  
changes	  in	  electron	  transport	  chain	  protein	  expression	  and	  decreased	  regulation	  of	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oxidative	  phosphorylation	  by	  uncoupling	  proteins.	  A	  greater	  understanding	  of	  these	  
























1. MPNST	  cell	  lines	  will	  have	  a	  higher	  glycolytic	  rates	  than	  NHSC.	  
Many	  other	  tumors	  have	  shown	  higher	  glycolytic	  compared	  to	  non-­‐
tumorigenic	  cells,	  but	  these	  parameters	  have	  never	  been	  examined	  in	  MPNST	  
sarcomas.	  We	  hypothesize	  that	  MPNST	  cell	  lines	  will	  have	  higher	  metabolic	  rates	  
than	  normal	  human	  Schwann	  cells	  because	  they	  need	  to	  produce	  more	  energy	  to	  
sustain	  increased	  growth	  rates.	  
	  
2. NF1-­‐patient	  derived	  MPNST	  cell	  lines	  will	  have	  lower	  mitochondrial	  
respiration	  than	  sporadic	  (Ras	  not	  hyperactivated)	  MPNST	  
We	   hypothesize	   that	   NF1	   patient	   derived	   MPNST	   cell	   lines	   will	   have	  
decreased	  mitochondrial	  respiration	  because	  these	  cells	  should	  have	  a	  hyperactive	  
Ras	   pathway.	   Ras	   hyperactivation	   may	   increase	   metabolic	   stress,	   giving	   rise	   to	  
mitochondrial	   dysfunction	   and	   increased	   autophagy/mitophagy	   creating	   a	   lower	  
mitochondrial	   content	   within	   the	   cells.	   In	   theory,	   tumor	   cells	   need	   more	   energy	  
during	   transformation	   and	   therefore	   increase	   mitochondrial	   respiration.	   After	  
tumor	   transformation,	   they	   shift	   their	   energy	   production	   in	   a	   Warburg	   effect	  
(changing	  to	  become	  more	  glycolytic).	  We	  hypothesize	  that	  this	  shift	  will	  ultimately	  
result	   in	   a	   new	  metabolic	   steady	   state	   with	   mitochondria	   content	   corresponding	  






	   Malignant	   peripheral	   nerve	   sheath	   tumors	   currently	   have	   no	   effective	  
chemotherapy.	   Half	   of	   all	   MPNST	   occur	   in	   the	   disease	   NF1.	   Mutations	   in	  
neurofibromin,	  a	  negative	  regulator	  of	  the	  Ras	  oncogene,	  can	  lead	  to	  increased	  Ras	  
signaling	   and	   cause	  NF1.	   Tumor	   cells	   often	   experience	  metabolic	   remodeling	   to	   a	  
more	   glycolytic	   state	   in	   support	   an	   increased	   growth	   rate;	   the	   metabolic	   change	  
ultimately	  depend	  on	  the	  energy	  requirements	  dictated	  by	  the	  oncogenic	  mutations.	  	  
Ras	   transformed	   tumor	   cells	   experience	   increased	   mitochondrial	   dysfunction	  
stemming	  from	  metabolic	  stress	  and	  increased	  mitophagy/autophagy	  among	  other	  
possibilities.	   This	   study	   used	   Extracellular	   flux	   analysis,	   Western	   blot,	  
immunocytochemistry,	   and	   ROS	   assays	   to	   characterize	   the	   metabolic	   profiles	   of	  
common	  MPNST	   cell	   lines.	  We	  describe	  here	  how	   they	  differ	   from	  normal	  human	  




































The	  MPNST	  cell	  lines	  grew	  in	  DMEM/High	  Glucose	  Media	  (HyClone,	  Cat.	  No.	  
SH30022.01)	   supplemented	   with	   10%	   FBS	   (HyClone,	   Cat.	   No.	   SH30910.03),	   1%	  
Penicillin	   and	   Streptomycin	   (10,000	   units/ml	   Penicillin	   and	   10,000	   units/ml	  
Streptomycin,	  HyClone,	  Cat.	  No.	   SV30010),	   and	  1%	  Amphotericin	  B	   (HyClone,	  Cat.	  
No.	   SV30078.01).	   	   Primary	   normal	   human	   Schwann	   cells	   (NHSC)	   purchased	   from	  
Creative	   Bioarray	   (Cat.	   No.	   CSC-­‐7715W)	   grew	   in	   media	   provided	   by	   the	   supplier	  
(Creative	  Bioarray,	  Cat.	  No.	  CSC-­‐7715WM)	  supplemented	  with	  1%	  Amphotericin	  B	  
(HyClone,	  Cat.	  No.	  SV30078.01).	  The	  Schwann	  cell	  media	  formulation	  was	  5%	  FBS,	  
1%	  Schwann	  cell	  growth	  serum,	  and	  1%	  Penicillin	  and	  Streptomycin.	  All	  lines	  grew	  
on	  cell	  culture	  treated,	  55	  cm2	  dishes	  (Corning,	  Cat.	  No.	  430167).	  NHSC	  dishes	  were	  
coated	  with	  2.0	  mg/cm2	  poly-­‐L-­‐lysine	  (Cultrex,	  Cat.	  No.	  3438-­‐100-­‐01).	  Cell	   culture	  
occurred	  in	  a	  Thermo	  Scientific	  1300	  Series	  A2,	  Class	  II	  biosafety	  cabinet	  employing	  
aseptic	   technique.	   Cell	   lines	   were	   incubated	   in	   a	   humidified	   Thermo	   Scientific	  
Forma	   Series	   II	  Water	   Jacket	   CO2	   Incubator	   at	   37	   °C	   and	  7.5%	  CO2/air	   (Yang	   and	  
Ylipää	   et	   al.,	   2011).	   Cells	   were	   monitored	   closely	   and	   passaged	   upon	   reaching	  
approximately	   85%	   confluence	   using	   0.05%	   trypsin-­‐0.01%	   EDTA	   (Quality	  
Biological,	   INC,	   Cat.	   No.	   118-­‐087-­‐721).	   All	   cell	   lines	   were	   utilized	   in	   experiments	  







	   The	   S100	   protein	   family	   are	   normally	   expressed	   in	   cells	   derived	   from	   the	  
neural	   crest	  and	  can	  be	  used	  as	  a	  marker	   for	  Schwann	  cells.	   S100	  expression	  was	  
used	  to	  determine	  the	  purity	  of	  the	  purchased	  normal	  human	  Schwann	  cells	  (NHSC).	  
NHSC	  were	   seeded	  on	  CultureSlides	   at	   2.0	   x105	   cells	  per	  well	   (BD	  Falcon,	  Ref	  No.	  
354108)	  coated	  with	  2.0	  µg/cm2	  poly-­‐L-­‐lysine	  (Cultrex,	  Cat.	  No.	  3438-­‐100-­‐01).	  The	  
slides	   incubated	   overnight	   in	   7.5	  %	   CO2/air	   (Yang	   and	   Ylipää	   et	   al.,	   2011).	   	   Cells	  
were	  washed	  (3x)	  with	  1x	  PBS	  and	  fixed	  with	  4%	  paraformaldehyde	  (Acros,	  41678-­‐
5000)	   pH	   =	   7.4	   for	   15	  minutes.	   Slides	   were	   washed	   twice	   with	   cold	   1x	   PBS	   and	  
blocked	   for	   1	   hour	   using	   10%	   normal	   goat	   serum	   (NGS)	   in	   1x	   PBS.	   Cells	   were	  
probed	  with	  anti-­‐S100	  antibody	  (Dako,	  Code	  No.	  Z	  0311)	  at	  a	  1:400	  dilution	  in	  10%	  
NGS/PBS	   overnight	   at	   4	   °C.	   Slides	  were	  washed	   the	   next	   day	   (3x)	   and	   incubated	  
with	  Rhodamine	  (TRITC)-­‐conjugated	  Goat	  Anti-­‐Rabbit	  secondary	  antibody	  (Jackson,	  
Code	   No.	   111-­‐025003)	   at	   1:100	   dilution	   in	   10%	   NGS/PBS	   for	   1	   hour	   at	   room	  
temperature.	   	   Next	   the	   slides	   were	   stained	   with	   4’,6-­‐diamidino-­‐2-­‐phenylindole	  
(DAPI)	  (Thermo	  Scientific,	  No.	  62248)	  at	  a	  1:1000	  dilution	  in	  PBS	  for	  5	  minutes	  at	  
room	   temperature.	   Slides	   were	   washed	   (3x)	   with	   PBS	   and	   coverslipped	   using	  
Fluoromount-­‐G	  mounting	  media	  (SouthernBiotech,	  Cat.	  No.	  0100-­‐01).	  Images	  were	  
taken	   using	   an	   Olympus	   BX51	   Fluorescent	  Microscope	   and	  NIS	   Elements	   (Nikon)	  
imaging	  software.	  TRITC	  was	  excited	  at	  550	  nm	  and	  emitted	  light	  at	  570	  nm,	  while	  
DAPI	  was	   excited	   at	   341	   nm	   and	   emitted	   light	   at	   452	   nm.	   Analysis	   of	   the	   images	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consisted	   of	   determining	   whether	   all	   nuclei	   stained	   with	   DAPI	   also	   stained	   with	  























Extracellular	  Flux	  Analysis	  
Extracellular	   acidification	   and	   oxygen	   consumption	  were	  monitored	   in	   live	  
cells	   with	   an	   Extracellular	   Flux	   (XF)	   24	   Analyzer	   (Seahorse	   Bioscience,	   North	  
Billerica,	  MA,	  USA).	  	  Extracellular	  acidification	  rate	  (ECAR)	  and	  oxygen	  consumption	  
rate	  (OCR)	  are	  indicators	  of	  glycolysis	  and	  mitochondrial	  respiration.	  The	  Analyzer	  
used	   fluorophores	   that	   change	   emission	   intensity	   in	   response	   to	   oxygen	   and	   pH	  
levels	   in	  the	  extracellular	  space.	  The	  rates	  were	  normalized	  to	  the	  number	  of	  cells	  
plated.	  Figure	  3	  shows	  the	  Extracellular	  Flux	  Analysis	  experimental	  set	  up.	  
Cells	  were	   liberated	   from	   dishes	  with	   0.05%	   trypsin-­‐0.01%	  EDTA	   solution	  
(Quality	   Biological,	   INC,	   Cat.	   No.	   118-­‐087721)	   and	   counted	   using	   a	   dye	   exclusion	  
method	  utilizing	  Trypan	  blue	   solution	   (HyClone,	  Cat.	  No.	   SV30084.01).	   Solubilized	  
cells	  were	  diluted	  to	  10x	  the	  desired	  density	  and	  were	  seeded	  in	  100	  µl	  of	  growth	  
media	   on	   Seahorse	   Bioscience	   V7	   plates	   (Part	   No.	   100777-­‐004)	   coated	   with	   2.0	  
µg/cm2	  poly-­‐L-­‐lysine	  (Cultrex,	  Cat.	  No.	  3438-­‐100-­‐01)	  for	  NHSC	  or	  1.6	  µg/cm2	  mouse	  
laminin	   (Corning,	  Cat.	  No.	  354232)	   for	  MPNST	  cell	   lines.	   	  The	  STS26T,	  90-­‐8,	   S462	  
were	   seeded	   at	   4.0	   x105	   cells	   per	   well,	   while	   NHSC	   and	   ST88-­‐14	   cell	   lines	   were	  
seeded	   at	   8.0	   x105	   cells	   per	   well.	   Seeding	   number	   was	   established	   by	   cellular	  
morphology	   and	   drug	   response,	   following	   the	   manufacturer’s	   direction	   (data	   not	  
shown).	   To	   prevent	   edge-­‐effects,	   a	   two	   step	   seed	  method	   was	   employed;	   seeded	  
plates	  remained	  in	  the	  hood	  at	  room	  temperature	  for	  1	  hour	  before	  being	  moved	  to	  
the	   incubator	   for	  1	  hour.	  After	  resting,	  150	  μl	  of	  growth	  media	  was	  added	  to	  each	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well.	  The	  plates	  were	  incubated	  overnight	  in	  7.5%	  CO2/air	  at	  37	  °C	  (Yang	  and	  Ylipää	  
et	  al.,	  2011).	  
The	  XF24	  Extracellular	  Flux	  analyzer	  sensor	  cartridge	  was	  hydrated	  with	  1	  
ml	  of	  calibrant	  (Seahorse	  Bioscience,	  Part	  No.	  100840-­‐000)	  per	  well	  and	  allowed	  to	  
incubate	  overnight	  in	  ambient	  air	  at	  37	  °C.	  Reconstitution	  of	  the	  XF	  Glycolysis	  Stress	  
Test	   Kit	   (Seahorse	   Bioscience,	   Part	   No.	   103015-­‐100)	   and	   XF	  Mito	   Stress	   Test	   Kit	  
(Seahorse	  Bioscience,	  Part	  No.	  101706-­‐100)	  followed	  manufacturer	  directions.	  	  
In	   these	  experiments,	  growth	  media	  was	  replaced	  with	  525	  μl	  assay	  media.	  
Glycolysis	  Stress	  Test	  assay	  media	  consisted	  of	  unbuffered	  XF	  Base	  Medium	  Minimal	  
DMEM	   (Seahorse	   Bioscience,	   Part	  No.102353-­‐100)	   supplemented	  with	   2.5	  mM	  L-­‐
glutamine	   (Hyclone,	   Cat.	   No.	   SH30034.02).	   While	   the	   Mitochondrial	   Stress	   Test	  
assay	   media	   was	   comprised	   of	   unbuffered	   XF	   Base	   Medium	   Minimal	   DMEM	  
supplemented	   with	   2.5	   mM	   L-­‐glutamine,	   2.0	   mM	   sodium	   pyruvate	   (Sigma	   Life	  
Science,	  S8636)	  and	  25.0	  mM	  D-­‐glucose	  (Sigma	  Life	  Science,	  Cat.	  No.	  G7528-­‐250G).	  
The	   D-­‐glucose	   concentration	   (25.0	   mM)	   was	   used	   in	   the	   stress	   test	   assay	   media	  
because	  the	  same	  concentration	  was	  present	  in	  the	  cell	  lines’	  normal	  growth	  media.	  
XF	  Base	  Medium	  Minimal	  DMEM	  does	  not	  natively	  contain	  D-­‐glucose.	  Assay	  media	  
was	  adjusted	  to	  pH	  =	  7.35	  ±	  0.05	  at	  37	  °C	  and	  filtered	  using	  0.2	  μm	  pore	  disposable	  
filter	  units	  (Thermo	  Scientific,	  Cat.	  No.	  09-­‐741-­‐04).	  The	  cells	  incubated	  for	  1	  hour	  in	  
assay	   media	   in	   a	   CO2-­‐free	   incubator	   to	   deplete	   bicarbonate	   buffering	   before	  
analysis.	   Stress	   Tests	   used	   mix/wait/measure	   times	   of	   3/0/3	   min,	   75	   μl	   drug	  
injections,	   and	   took	  3	  measurements	  after	  each	   condition	   change.	  All	   experiments	  
were	  conducted	  at	  37	  °C	  in	  ambient	  air.	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FIGURE	  3	  	  	  
XF24	  Extracellular	  Flux	  Analyzer	  Experimental	  Setup	  
Attached	   to	   the	   probes	   on	   the	   sensor	   cartridge	   are	   two	   fluorophore	   dots	   that	  
respond	   to	   changes	   in	   extracellular	   pH	   and	   oxygen.	   Drugs	   are	   injected	  
pneumatically	   by	   a	   puff	   of	   air.	   The	   Extracellular	   Flux	   Analyzer	   calculates	   rates	   of	  
extracellular	   flux	   for	   protons	   (pH)	   and	   oxygen.	   Image	   used	  with	   permission	   from	  






























GLYCOLYSIS	  STRESS	  TEST	  
The	  XF24	   analyzes	   the	   extracellular	   change	   in	   pH	   and	   calculates	   a	   rate	   for	  
each	  time	  point.	  The	  change	  in	  pH	  is	  a	  product	  of	  and	  therefore	  directly	  related	  to	  
glycolytic	   flux.	  The	  Glycolytic	  profile	   for	  each	  cell	   line	  comes	   from	  rate	  differences	  
between	   specific	   times	   in	   the	   course	   of	   the	   experiment.	   Figure	   4	   shows	   a	  
generalized	  Glycolysis	   Stress	  Test	   and	  provides	  general	   relationships	  between	   the	  
Glycolytic	   profile	   components	   and	   the	   rate	   data	   output.	   Initial	   extracellular	  
acidification	   rates	  was	  measured	   in	  media	  without	   glucose	   then	  10.0	  mM	  Glucose	  
was	   injected	   and	   the	   ECAR	   increased	   in	   response	   to	   the	   increased	   utilization	   of	  
glucose	  by	  glycolysis	  and	  production	  of	  lactic	  acid.	  Oligomycin	  A	  (1	  μM)	  was	  added	  
next.	   Oligomycin	   A	   inhibits	   Complex	   V	   (ATP	   synthase)	   resulting	   in	   increased	  
glycolysis	   (and	   therefore	   proton	   production	   and	   excretion)	   to	   satisfy	   the	   cellular	  
energy	  needs	  no	  longer	  being	  met	  by	  oxidative	  phosphorylation.	  2-­‐deoxy-­‐D-­‐glucose	  
(2-­‐DG)	  was	  added	  last	  and	  competitively	  inhibits	  hexokinase,	  the	  enzyme	  catalyzing	  
the	  first	  step	  of	  glucose	  degradation	  in	  glycolysis.	  The	  100	  mM	  2-­‐DG	  concentration	  
used	  in	  the	  assay	  ensures	  complete	  hexokinase	  saturation	  allowing	  the	  ascription	  of	  
ECAR	  measured	   after	   2-­‐DG	   addition	   to	   other	   proton	   producing	   processes	   besides	  
glycolysis.	   The	   Glycolysis	   Stress	   Test	   assay	   data	   values	   are	   comprised	   of	   the	  






FIGURE	  4	  	  
Glycolysis	  Stress	  Test	  	  
A	  general	  Glycolysis	   Stress	  Test	   output,	   the	  picture	  demonstrates	   the	   relationship	  
between	  Glycolytic	  Profile	  parameters.	  Oligomycin	   (A)	  =	   inhibits	  ATP	   synthase,	  2-­‐






























MITOCHONDRIAL	  STRESS	  TEST	  
The	   Mito	   Stress	   Test	   measures	   the	   consumption	   of	   oxygen	   from	   the	  
extracellular	   space.	  Oxygen	   is	   the	   final	   electron	  acceptor	   in	   the	  electron	   transport	  
chain	  and	  is	  a	  good	  measure	  of	  mitochondrial	  respiratory	  activity.	  The	  Mito	  Stress	  
Test	  used	  sequential	  injections	  of	  1.0	  μM	  Oligomycin	  A,	  1.0	  μM	  carbonyl	  cyanide	  4-­‐
(trifluoromethoxy)phenylhydrazone	  (FCCP),	  and	  1.0	  μM	  Rotenone	  and	  Antimycin	  A	  
to	   assess	   mitochondrial	   function.	   	   Basal	   Respiration	   was	   measured	   before	   drug	  
addition	  and	   is	   the	  normal	  rate	  of	  oxygen	  consumption	   for	   the	  cells.	  Oligomycin	  A	  
was	   injected	   first	   and	   inhibits	  Complex	  V	   (ATP	  Synthase).	  OCR	  decreased	  because	  
the	  only	  oxygen	  being	  consumed	  to	  sustain	  the	  proton	  electrochemical	  gradient	  was	  
in	  support	  of	  proton	  leak.	  	  The	  next	  drug	  added	  was	  FCCP–an	  ionophore	  that	  acts	  as	  
a	  proton	   channel,	   providing	  protons	  a	   route	  across	   lipid	  bilayers.	   FCCP	  dissipated	  
the	   proton	   gradient	   driving	   ATP	   synthase	   mediated	   ATP	   production	   and	   proton	  
leak.	   The	   gradient	   dissolution	   uncouples	   the	   electron	   transport	   chain	   from	   ATP	  
synthesis	   and	   allows	   the	   electron	   transport	   chain	   (Complexes	   I,	   II,	   III,	   and	   IV)	   to	  
work	   at	   the	   maximal	   rate.	   Rotenone	   and	   Antimycin	   A	   were	   added	   last	   and	  
simultaneously.	  Rotenone	  and	  Antimycin	  A	  inhibit	  Complexes	  I	  and	  III,	  respectively.	  
The	   inhibition	   of	   Complex	   I	   and	   III	   shut	   down	   the	   electron	   transport	   chain	   and	  
remaining	   OCR	   measured	   is	   attributed	   to	   processes	   other	   than	   mitochondrial	  
respiration.	   Mitochondrial	   Stress	   Test	   assay	   data	   are	   comprised	   of	   the	   following	  




FIGURE	  5	  	  	  
Mitochondria	  Stress	  Test	  
A	   general	  Mitochondrial	   Stress	   Test	   that	   demonstrates	   the	   relationships	   between	  
Mitochondrial	  Metabolic	  Profile	  parameters.	  Oligomycin	  (A)	  =	  inhibits	  ATP	  synthase	  
(Complex	  V),	  FCCP	  =	  dissipates	  electrochemical	  proton	  gradient,	  Rotenone	  =	  inhibits	  





























REACTIVE	  OXYGEN	  SPECIES	  ASSAY	  
STS26T,	  90-­‐8,	  S462	  were	  seeded	  at	  4.0	  x105	  cells	  per	  well,	  while	  NHSC	  and	  	  
ST88-­‐14	  cell	  lines	  were	  seeded	  at	  8.0	  x105	  cells	  per	  well	  of	  a	  96-­‐well	  plate	  (Falcon,	  
REF:	  353072)	  coated	  with	  2.0	  µg/cm2	  poly-­‐L-­‐lysine	  (Cultrex,	  Cat.	  No.	  3438-­‐	  100-­‐01)	  
for	  NHSC	  or	  1.6	  µg/cm2	  mouse	   laminin	  (Corning,	  Cat.	  No.	  354232)	   for	  MPNST	  cell	  
lines.	   Cell	   lines	  were	   plated	   at	   different	   densities	   to	  mirror	   the	   Extracellular	   Flux	  
Analyzer	   experimental	   set	   up.	   The	   cells	   incubated	   overnight	   at	   37	   °C	   at	   7.5%	  
CO2/air	   in	   phenol	   red	   free	   DMEM/High	   Glucose	   (HyClone,	   Cat.	   No.	   SH30284.01)	  
supplemented	   with	   1%	   FBS	   (HyClone,	   Cat.	   No.	   SH30910.03),	   1%	   Penicillin	   and	  
Streptomycin	  (HyClone,	  Cat.	  No.	  SV30010),	  and	  1%	  Amphotericin	  B	  (HyClone,	  Cat.	  
No.	  SV30078.01).	  	  	  
	   Cells	  were	  washed	   the	   next	   day	  with	   1x	   PBS	   and	   incubated	   in	   8.65	  mM	  5-­‐
(and-­‐6)-­‐chloromethyl-­‐2′,7′-­‐dichlorodihydrofluorescein	   diacetate,	   acetyl	   ester	   (CM-­‐
H2DCFDA)	  (Invitrogen	  Molecular	  Probes,	  Cat.	  No.	  C6827)	  dissolved	  in	  1x	  PBS	  for	  30	  
minutes.	  As	  the	  compounds	  are	  liable	  to	  undergo	  photo-­‐oxidation,	  care	  was	  taken	  to	  
limit	  exposure	  to	   light.	  Cells	  were	  washed	  with	  1x	  PBS	  (2x	  200ml)	  and	  allowed	  to	  
recover	  in	  the	  incubator	  with	  300	  ml	  of	  phenol	  red	  free	  DMEM/High	  Glucose	  for	  30	  
minutes.	   Fluorescence	   was	   measured	   using	   a	   BioTek	   Synergy	   H1	   Multi-­‐Mode	  
Reader	  with	  excitation	  at	  495	  nm	  and	  emission	  at	  527	  nm.	  The	  well	  intensities	  were	  
normalized	   to	   the	   seed	  density	   for	  each	  cell	   line,	   and	   then	  divided	  by	   the	  average	  
intensity	   for	  NHSC.	  The	  background	   fluorescence	  was	   taken	   into	   account	   for	   each	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cell	   line	   and	   results	   are	   reported	   as	   average	   fold	   change	   in	   ROS	   from	   NHSC	   ±	  
standard	  error	  of	  the	  mean.	  The	  Reactive	  Oxygen	  Species	  Assay	  groups	  were	  n=8.	  	  
CM-­‐H2DCFDA	   is	   non-­‐fluorescent	   and	   possesses	   two	   acetate	   groups	   that	  
decrease	   the	   polarity	   of	   the	   compound	   allowing	   it	   to	   easily	   pass	   through	   lipid	  
bilayers,	   once	   inside	   the	   cell	   endogenous	   esterases	   cleave	   the	   acetates,	   activating	  
the	   chemical.	   The	   compound	   also	   contains	   chloromethyl	   groups	   that	   react	   with	  
intracellular	  thiols	  supposedly	  increasing	  the	  retention	  of	  the	  compound	  within	  the	  
cell	  compared	  to	  other	  chemical	  derivatives.	  The	  inactive	  molecules	  are	  oxidized	  by	  
reactive	   oxygen	   species	   creating	   a	   fluorescent	   compound.	   Excitation	   of	   the	  
fluorescent	  compound	  allows	  the	  electrons	  to	  jump	  to	  higher	  energy	  orbital	  that	  will	  
then	   emit	   light	   when	   they	   decay	   back	   down	   to	   a	   lower	   energy	   orbital.	   Figure	   6	  














CM-­‐H2DCFDA	  ROS	  Assay	  	  
A	   schematic	   that	   details	   a	   possible	   mechanism	   of	   action	   for	   the	   CM-­‐H2DCFDA	  
determination	   of	   ROS	   levels.	   CM-­‐H2DCFDA	   =	   5-­‐(and-­‐6)-­‐chloromethyl-­‐2′,7′-­‐
































WESTERN	  BLOT	  ANALYSIS	  
	   PROTEIN	  COLLECTION	  
Cells	  (1.3	  x106	  per	  well)	  were	  seeded	  on	  a	  6-­‐well	  plate	  (Falcon,	  Ref.	  353046)	  
coated	  with	  2.0	  µg/cm2	  poly-­‐L-­‐lysine	   (Cultrex,	  Cat.	  No.	  3438-­‐100-­‐01)	   for	  NHSC	  or	  
1.6	   µg/cm2	   mouse	   laminin	   (Corning,	   Cat.	   No.	   354232)	   for	   MPNST.	   The	   cells	  
incubated	   overnight	   in	   their	   respective	   growth	   media	   and	   protein	   lysate	   was	  
collected	   the	   following	   day.	  While	   on	   ice,	   the	   cells	  were	  washed	  with	   1x	   PBS	   (3x	  
1ml)	  then	  300	  ml	  Lysis	  Buffer	  (25	  mM	  Tris-­‐HCl,	  pH	  7.4,	  150	  mM	  NaCl,	  0.1	  %	  SDS,	  1	  
%	  Triton	  X-­‐100,	  and	  1%	  deoxycholate)	  was	  added	  to	  each	  well.	  Cells	  were	  manually	  
scraped	  off	   the	  plate	   and	   triturated	   for	  30	   seconds	  until	   all	   visible	  occlusions	  had	  
broken	  apart.	  The	  solution	  was	  transferred	  to	  the	  1.5	  ml	  tubes	  on	  ice	  and	  spun	  at	  4	  
°C,	  1	  x105	  rpm	  for	  5	  minutes	  (Eppendorf,	  Centrifuge	  5424	  R).	  The	  supernatant	  was	  
transferred	  to	  fresh	  1.5	  ml	  tubes.	  	  
	   	  
PROTEIN	  QUANTIFICATION	  
Protein	   concentration	   was	   measured	   using	   the	   colorimetric	   Pierce	   BCA	  
Protein	  Assay	  Kit	  (Thermo	  Scientific,	  Prod.	  No.	  23227).	  The	  BCA	  Protein	  Assay	  Kit	  
uses	  a	  variation	  of	  the	  biuret	  reaction	  in	  which	  Cu2+	  reduces	  to	  Cu1+	  in	  the	  presence	  
of	  protein	  and	  is	  then	  chelated	  by	  bicinchoninic	  acid	  (BCA)	  (Smith,	  et	  al	  1985).	  Two	  
BCA	   molecules	   combine	   with	   one	   Cu1+	   resulting	   in	   a	   purple	   product	   with	   an	  
absorbance	  at	  562	  nm.	  A	  sample	  of	  each	  protein	   lysate	  was	  diluted	  1:10	  in	  double	  
distilled	  water.	  The	  sample	  to	  working	  reagent	  ratio	  was	  1:20	  for	  a	  total	  volume	  of	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200	  ml.	   The	   96-­‐well	   plate	   was	   shaken	   for	   30	   sec	   at	   200	   rpm	   (Benchmark,	   Incu-­‐
Shaker	   10L)	   and	   then	   incubated	   for	   30	   min	   at	   37	   °C.	   The	   plate	   cooled	   to	   room	  
temperature	  and	   the	  absorbance	  was	  measured	  using	  a	  BioTek	  Synergy	  H1	  Multi-­‐
Mode	   Reader	   at	   562	   nm.	   Each	   absorbance	   value	   was	   an	   average	   of	   two	  
measurements	  minus	  the	  average	  of	  two	  blanks.	  A	  linear	  curve	  of	  best	  fit	  modeled	  
the	  Beer’s	  Law	  relationship.	  	  
	  
GEL	  ELECTROPHORESIS	  
Gel	  electrophoresis	  separates	  proteins	  by	  size	  with	  smaller	  proteins	  running	  
faster	  than	  bigger	  ones.	  A	  12%	  resolving	  gel	  was	  made	  using	  Acrylamide/Bis	  (29:1)	  
30%	   Solution	   (4	  ml,	   Hoefer,	   GR329-­‐500),	   1.5	  M	   Tris-­‐HCL	  with	   pH	   =	   8.8	   (2.5	  ml),	  
10%	  SDS-­‐ddH2O	  (0.1	  ml),	  ddH2O	  (3.35	  ml),	  10%	  ammonium	  persulfate	  (50	  ml),	  and	  
Tetramethylethylenediamine	  (5	  µl	  TEMED).	  The	  glass	  plates	  were	  washed	  with	  70%	  
ethanol-­‐ddH2O	  before	  clamped	  into	  place	  and	  checked	  for	  leaks.	  	  
	   Volume	  of	  lysate	  equal	  to	  20	  µg	  of	  protein	  was	  added	  to	  1.5	  ml	  tubes	  with	  the	  
appropriate	   volume	   of	   6x	   Laemmli	   SDS	   Sample	   Buffer	   (Bioworld,	   Cat.	   No.	  
10570019-­‐2)	   to	  dilute	   it	   to	  1x	  and	  10%	  (v/v)	  b-­‐mercaptoethanol	   (Acros	  Organics,	  
Code:	   125472500).	   The	   tubes	   were	   boiled	   at	   95	   °C	   (Benchmark	   myBlock)	   for	   5	  
minutes,	   spun	   for	  30	  seconds	   (BioExcell	  MiniFuge),	  and	  placed	  on	   ice	   to	  cool.	  The	  
sodium	   dodecyl	   sulfate	   (SDS)	   gel	   lanes	   were	   loaded	   with	   the	   20	   µg	   of	   protein.	  
Protein	  ladder	  (10	  µl,	  Amersham,	  Prod.	  Code:	  RPN800E)	  was	  loaded	  and	  later	  used	  
to	  determine	  relative	  protein	  size.	  The	  gel	  was	  run	  at	  100V	  for	  90	  minutes	  in	  1x	  SDS	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Running	   Buffer.	   Stock	   10x	   SDS	   Running	   Buffer	   is	   comprised	   of	   0.25	   M	   Tris	   Base	  
(Fisher	   Scientific,	   BP152-­‐10),	   1.92	  M	   Glycine	   (Fisher	   Scientific,	   BP381-­‐5),	   and	   35	  
mM	  SDS	  (Fisher	  Scientific,	  BP166-­‐500)	  in	  double	  distilled	  water.	  	  
	   	  
	   MEMBRANE	  TRANSFER	  
After	   separation,	   proteins	   were	   transferred	   to	   a	   more	   stable	   membrane.	  
Foam,	  paper	  and	  0.2	  µm	  nitrocellulose	  membrane	  (Bio-­‐Rad,	  162-­‐0112)	  were	  soaked	  
in	  1x	  Transfer	  Buffer	   for	  5	  minutes.	  Stock	  10x	  Transfer	  Buffer	   is	  made	  of	  250	  mM	  
Tris	  Base	  (Fisher	  Scientific,	  BP152-­‐10)	  and	  1.92	  M	  Glycine	  (Fisher	  Scientific,	  BP381-­‐
5)	  in	  double	  distilled	  water.	  1x	  Transfer	  Buffer	  is	  made	  from	  800	  ml	  of	  10x	  Transfer	  
Buffer,	  1600	  mL	  methanol	   (Fisher	  Scientific,	  BP1105-­‐4),	  and	  5.6	  L	  double	  distilled	  
water.	   	   Each	   layer	  was	  wetted	  with	  1x	  Transfer	  Buffer	   as	   they	  were	   layered	  with	  
caution	  to	  avoid	  bubbles.	  Transfer	  ran	  at	  100V	  for	  1	  hour	  with	  ice	  surrounding	  the	  
entire	  apparatus	  to	  keep	  the	  process	  cool	  limiting	  gel	  degradation.	  	  
	  
	   DETECTION	  
The	  membrane	  was	  blocked	  with	  5%	  (w/v)	  non-­‐fat	  dry	  milk	  (Kroger	  Brand)	  
in	   TBST	   (20	  mM	  Tris	   HCl	   (Fisher	   Scientific,	   BP153-­‐500)	   pH	   =	   7.5,	   150	  mM	  NaCl,	  
0.05%	  (v/v)	  Tween	  20	  (Fisher	  Scientific,	  BP337-­‐500)	  in	  double	  distilled	  water)	  for	  1	  
hour	  at	   room	   temperature.	   	  The	  membrane	  was	  probed	  with	  primary	  antibody	   in	  
2%	   (w/v)	   of	   non-­‐fat	   dry	   milk	   in	   TBST	   overnight	   at	   4	   °C	   or	   1	   hour	   at	   room	  
temperature.	   The	   primary	   antibodies	   used	   are	   as	   follows:	   anti-­‐Complex	   I	   subunit	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NDUFB8	   mouse	   monoclonal	   (Invitrogen	   Molecular	   Probes,	   Cat.	   No.	   459210)	   in	   a	  
1:1000	   dilution,	   anti-­‐Cytochrome	  C	   rabbit	  monoclonal	   (Abcam,	   Cat.	   No.	   04-­‐1043),	  
anti-­‐Complex	   IV	   subunit	   IV	   mouse	   monoclonal	   antibody	   (Invitrogen	   Molecular	  
Probes,	   Cat.	   No.	   A21347)	   in	   a	   1:1000	   dilution,	   anti-­‐Complex	   V	   (ATP	   Synthase)	  
subunit	   alpha	  mouse	  monoclonal	   antibody	   (Invitrogen	  Molecular	   Probes,	   Cat.	   No.	  
459240)	   in	  a	  1:1000	  dilution,	   anti-­‐UCP2	   (G-­‐6)	  mouse	  monoclonal	   antibody	   (Santa	  
Cruz	   Biotechnology,	   sc-­‐390189)	   in	   a	   1:500	   dilution,	   anti-­‐nNOS	   rabbit	  monoclonal	  
antibody	   (Cell	   Signaling,	   #4231)	   in	   a	   1:1000	   dilution,	   and	   anti-­‐eNOS	   rabbit	  
monoclonal	  antibody	  (Cell	  Signaling,	  #9586)	  in	  a	  1:1000	  dilution.	  	  
	   The	  membranes	  were	  washed	   the	   next	  morning	  with	   TBST	   	   (3x	   10	  ml)	   to	  
remove	   unbound	   primary	   antibody,	   then	   were	   probed	   for	   1	   hour	   at	   room	  
temperature	  with	  the	  secondary	  antibody	  in	  2%	  (w/v)	  non-­‐fat	  dry	  milk/TBST.	  The	  
secondary	   antibodies	   used	   were:	   HRP-­‐conjugated	   anti-­‐mouse	   IgG	   (Cell	   Signaling	  
Technology,	  #7076)	   in	  a	  1:3000	  dilution	  and	  HRP-­‐conjugated	  anti-­‐rabbit	   IgG	   (Cell	  
Signaling,	   #7074)	   in	   a	   1:1000	   dilution.	   Unbound	   secondary	  was	  washed	   out	  with	  
TBST	   (3x	   10	   ml)	   followed	   by	   PBS	   (1x	   10	   ml).	   	   The	   purpose	   of	   the	   secondary	  
antibody	  is	  to	  increase	  the	  resolution	  of	  the	  technique	  by	  forcing	  a	  second	  round	  of	  
selection	  on	  the	  protein	  of	  interest.	  
	  The	   detection	   process	   uses	   a	   combination	   of	   two	   reagents,	   luminol	   and	  
hydrogen	  peroxide,	  and	  the	  HRP	  conjugated	  to	  the	  secondary	  antibody.	  Immobilon	  
Western	   Chemiluminescent	   HRP	   substrate	   (Millipore,	   Cat.	   No.	   WBKLS0500)	   was	  
mixed	   in	  a	  1:1	   ratio	  and	  applied	   to	   the	  membrane	   for	  about	  2	  minutes.	  Hydrogen	  
peroxide	   is	   cleaved	   by	  HRP	   into	   an	   unstable	   and	   highly	   reactive	   hydroxyl	   radical	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that	   reacts	   with	   luminol	   creating	   a	   high	   energy	   intermediate.	   The	   high	   energy	  
intermediate	  emits	  blue	  visible	   light	  as	  the	  high	  energy	  electron	  decays	  to	  a	   lower	  
energy	   orbital.	   The	   light	   given	   off	   was	   detected	   by	   blue	   autoradiophrahy	   film	  
(WorldWide	  Medical	  Products,	  Inc.,	  BioExcell,	  41101002).	  Film	  was	  processed	  using	  
a	  Konica	  Minolta	  SRX-­‐101A	  Medical	  Film	  Processor.	  	  	  
	   Even	   protein	   loading	   was	   determined	   by	   comparing	   levels	   of	   β−actin.	  
Remaining	   ECL	   was	   washed	   out	   with	   TBST	   (2x	   10	   ml)	   and	   the	   membrane	   was	  
stripped	   for	   15	   minutes	   with	   Restore	   Western	   Blot	   Stripping	   Buffer	   (Thermo	  
Scientific,	  Prod.	  #	  21059).	  The	  stripping	  buffer	  was	  washed	  out	  using	  TBST	  3x	  10	  
minutes	   and	   the	  membrane	  was	   blocked	  with	   5%	  non-­‐fat	   dry	  milk	   in	   TBST	   for	   1	  
hour.	   The	   membrane	   was	   probed	   with	   β-­‐actin	   rabbit	   monoclonal	   antibody	  
conjugated	  with	  horseradish	  peroxidase	  (HRP)	  (Cell	  Signaling	  Technology,	  #5125)	  
in	   a	   1:4000	   dilution	   in	   2%	   non-­‐fat	   dry	   milk	   TBST	   overnight	   at	   4	   °C	   or	   at	   room	  
temperature	  for	  1	  hour.	  Excess	  antibody	  was	  washed	  out	  with	  TBST	  (3x	  10	  ml)	  and	  
ECL	  was	  applied	  and	  film	  was	  re-­‐exposed.	  	  
	   Relative	  protein	  expression	   levels	  were	   calculated	  by	  dividing	  each	  MPNST	  
band	  densitometry	  measurement	  by	  the	  NHSC	  densitometry	  measurement	  for	  each	  







	  	   Values	  represented	  as	  mean	  ±	  standard	  error	  of	  the	  mean.	  Data	  was	  analyzed	  
using	  Microsoft	  Excel	  2011.	  Figures	  were	  made	  with	  Photoshop	  Elements	  12	  Editor.	  
One-­‐way	  ANOVA	  with	  Tukey	  post	  hoc	  was	  calculated	  using	  Prism	  3.03.	  P-­‐values	  less	  



















































NORMAL	  HUMAN	  SCHWANN	  CELLS	  ARE	  A	  PURE	  CULTURE	  
	   	  
	   S100	   is	   a	   family	   of	   proteins	   that	   contain	   calcium-­‐binding	   sites	   and	   are	  
normally	  found	  in	  cells	  derived	  from	  the	  neural	  crest.	  S100	  expression	  is	  used	  as	  a	  
marker	   for	  Schwann	  cells.	   	  Normal	  human	  Schwann	  cells	  purchased	   from	  Creative	  
Bioarray	  were	  probed	  for	  S100	  expression,	  and	  counterstained	  with	  DAPI.	  DAPI	  is	  a	  
nuclear	   marker.	   The	   finding	   that	   all	   DAPI	   stained	   nuclei	   also	   stained	   for	   S100	  
indicates	  that	  the	  NHSC	  were	  not	  contaminated	  with	  other	  cell	  types	  like	  fibroblasts	  
and	   are	   a	   pure	   culture.	   Figure	   7	   contains	   representative	   images	   of	   NHSC	   stained	  



















FIGURE	  7	  	  
NHSC	  are	  a	  Pure	  Culture	  
S100	  protein	  is	  used	  as	  a	  marker	  of	  Schwann	  Cells.	  DAPI	  is	  a	  nuclear	  stain.	  All	  nuclei	  
co-­‐localized	  with	  S100	  staining	  indicating	  that	  the	  normal	  human	  Schwann	  cell	  line	  
used	   is	  not	  contaminated	  with	  other	  cell	   types	  and	   is	  a	  pure	  Schwann	  cell	  culture.	  



































































NF1-­‐DEFICIENT	  MPNST	   LINES	   HAVE	   LOWER	   GLYCOLYTIC	   RATES	   THAN	   NF1-­‐
WILDTYPE	  
To	  determine	  whether	  NF1	  plays	  a	  role	   in	  metabolism	  several	  different	  cell	  
lines	  were	  submitted	  to	  metabolic	  stressors.	  	  The	  STS26T	  has	  been	  used	  extensively	  
as	  the	  NF1-­‐wildtype	  MPNST	  line.	  The	  presence	  of	  neurofibromin	  was	  confirmed	  in	  
STS26T	  (Mattingly	  et	  al.,	  2006).	  The	  ST88-­‐14,	  90-­‐8,	  and	  S462	  lines	  are	  derived	  from	  
NF1	  patient	  MPNST	  and	  are	  used	  to	  model	  neurofibromin	  deficient	  cells	  (Patel	  et	  al.,	  
2012;	   Wu	   et	   al.,	   2014).	   Figure	   8B	   contains	   the	   extracellular	   acidification	   rates	  
(ECAR)	  outputs	  for	  these	  cell	  lines.	  
Glycolysis	  ECAR	  (Figure	  8C)	  was	  investigated	  first	  using	  D-­‐glucose.	  Glycolytic	  
rate	   is	   important	   to	   human	  MPNST	   outcomes	   because	   the	   tumors	   are	   commonly	  
monitored	   and	   graded	   using	   FDG	   positron	   emission	   tomography.	   The	   Glycolysis	  
extracellular	  acidification	  rates	  (mean	  ±	  SEM)	  in	  µpH/min/cell	  are:	  0.14	  ±	  0.02	  for	  
NHSC,	  0.77	  ±	  0.07	  for	  STS26T,	  0.24	  ±	  0.01	  for	  ST88-­‐14,	  0.30	  ±	  0.03	  for	  90-­‐8,	  0.62	  ±	  
0.02	   for	   S462	   (Figure	   8C).	   All	  MPNST	   cell	   lines	   have	   significantly	   faster	   glycolytic	  
rates	   than	   NHSC	   except	   for	   ST88-­‐14,	   which	   was	   higher	   but	   not	   significantly	   so.	  	  
STS26T	  were	  significantly	  higher	  than	  all	  other	  lines	  while	  S462	  were	  significantly	  
different	  from	  all	  other	  lines.	  	  
The	   second	   parameter	   explored	  was	   Glycolytic	   Capacity	   (Figure	   8D)	   using	  
Oligomycin	   A	   and	   D-­‐glucose.	   The	   Glycolytic	   Capacity	   approaches	   the	   maximum	  
glycolytic	   potential	   following	   ATP	   synthase	   inhibition.	   Glycolytic	   Capacity	  
demonstrates	  the	  glycolytic	  rate	  required	  to	  meet	  all	  cellular	  energy	  requirements	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and	   is	   important	   to	   cancer	   metabolism	   because	   it	   indicates	   how	   energetic	  
transformed	   cells	   are	   and	   how	   glycolytic	   they	   could	   be.	   The	   Glycolytic	   Capacity	  
ECAR	   (mean	   ±	   SEM)	   in	   µpH/min/cell	   are:	   0.40	   ±	   0.04	   for	   NHSC,	   1.95	   ±	   0.10	   for	  
STS26T,	   0.59	   ±	   0.01	   for	   ST88-­‐14,	   0.76	   ±	   0.06	   for	   90-­‐8,	   and	   1.24	   ±	   0.04	   for	   S462	  
(Figure	   8D).	   	   All	  MPNST	   cells	   lines	   have	   a	   significantly	   higher	   Glycolytic	   Capacity	  
than	  NHSC	  with	  the	  exception	  of	  ST88-­‐14,	  which	  was	  higher	  but	  not	  significantly	  so.	  
The	   NF1-­‐wildtype	   MPNST	   line’s	   (STS26T)	   Glycolytic	   Capacity	   was	   significantly	  
higher	   than	   the	  other	   lines.	  NF1-­‐deficient	  MPNST	  cell	   lines	  were	   significant	   lower	  
than	  NF1-­‐wildtype	  MPNST.	  The	  90-­‐8	  line	  was	  significantly	  different	  from	  all	  others	  
except	  for	  ST88-­‐14.	  S462	  were	  significantly	  different	  from	  all	  other	  cell	  lines.	  
Glycolytic	  Reserve	  (Figure	  8E)	  shows	  the	  glycolytic	  rate	  increase	  required	  to	  
match	   the	   energy	   output	   by	  mitochondrial	   respiration.	   Glycolytic	   Reserve	   can	   be	  
used	   as	   evidence	   for	   glycolytic	   or	   mitochondrial	   respiratory	   protein	   activity	  
differences.	   Glycolytic	   Reserve	  was	   tested	   using	  D-­‐glucose	   and	  Oligomycin	   A.	   The	  
Glycolytic	  Reserve	  ECAR	  (mean	  ±	  SEM)	  in	  µpH/min/cell	  are:	  0.26	  ±	  0.05	  for	  NHSC,	  
1.18	  ±	  0.12	  for	  STS26T,	  0.35	  ±	  0.02	  for	  ST88-­‐14,	  0.45	  ±	  0.07	  for	  90-­‐8,	  and	  0.61	  ±	  0.05	  
for	   S462	   (Figure	  8E).	  The	  NF1-­‐deficient	  MPNST	  cell	   lines	  were	   significantly	   lower	  
than	   the	   NF1-­‐wildtpye	   MPNST;	   the	   STS26T	   line	   was	   significantly	   higher	   than	   all	  
other	  cell	  lines.	  All	  MPNST	  cell	  lines	  have	  significantly	  different	  Glycolytic	  Reserves	  
except	   for	   ST88-­‐14	   and	   90-­‐8.	   	   ST88-­‐14	  was	   not	   significantly	   different	   from	  NHSC	  
and	   90-­‐8.	   Glycolytic	   Reserve	   differences	   are	   probably	   due	   to	   variation	   in	   protein	  
expression	  or	  activity	  levels.	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FIGURE	  8	  
NF1-­‐DEFICIENT	  MPNST	   LINES	   HAVE	   LOWER	   GLYCOLYTIC	   RATES	   THAN	   NF1-­‐
WILDTYPE	  
	  (A)	  Representative	  depiction	  of	  Glycolytic	  Stress	  Test.	  (B)	  Glycolytic	  Stress	  Test	  for	  
NHSC	   and	  MPNST	   lines.	   NHSC	   and	   STS26T	   are	   NF1-­‐wildtype.	   ST88-­‐14,	   90-­‐8,	   and	  
S462	   are	   NF1-­‐deficient.	   (C)	   Glycolytic	   rate	   (D)	   Glycolytic	   Capacity	   (E)	   Glycolytic	  
Reserve.	  Results	  are	  mean	  ±	  SEM.	  n	  =	  5-­‐10.	  P	  values	  determined	  by	  one-­‐way	  ANOVA	  
with	  Tukey	  post	  hoc.	  	  NHSC	  =	  Normal	  Human	  Schwann	  Cells,	  2-­‐deoxy-­‐D-­‐glucose	  (2-­‐




















NF1-­‐DEFICIENT	  MPNST	  HAVE	   LOWER	  MITOCHONDRIAL	   RESPIRATION	   THAN	  
NF1-­‐WILDTYPE	  
To	   evaluate	   whether	   NF1	   status	   has	   a	   role	   in	   tumor	   oxidative	  
phosphorylation	  MPNST	  cell	  lines	  with	  and	  without	  functional	  NF1	  were	  submitted	  
to	  metabolic	  stressors.	  Figure	  9B	  is	  the	  Mito	  Stress	  Test	  data	  output.	  	  
ATP	  Production	  Oxygen	  Consumption	  Rate	   (OCR)	   (Figure	  9C)	   is	   the	   rate	  of	  
oxygen	  consumption	  by	  the	  electron	  transport	  chain	   to	  create	   the	  proton	  gradient	  
used	  by	  ATP	  synthase	  in	  the	  production	  of	  ATP.	  ATP	  Production	  OCR	  gives	   insight	  
into	  how	  a	  cell	  produces	  energy.	  High	  ATP	  production	  results	   from	  increased	  ATP	  
demand,	   while	   decreased	   ATP	   Production	   could	   be	   due	   to	   decreased	   substrate	  
availability	   (NADH,	   FADH2),	   electron	   transport	   chain	   damage,	   or	   decreased	   ATP	  
demand.	   Oligomycin	   A	   and	   Antimycin	   A/Rotenone	   were	   used	   to	   determine	   ATP	  
Production.	   ATP	   Production	   oxygen	   consumption	   rates	   (mean	   ±	   SEM)	   in	   fmol	  
O2/min/cell	  are:	  1.7	  ±	  0.3	  for	  NHSC,	  14	  ±	  1	  for	  STS26T,	  3.3	  ±	  0.6	  for	  ST88-­‐14,	  3.7	  ±	  
0.5	   for	  90-­‐8,	   and	  3.6	  ±	  0.6	   for	  S462	   (Figure	  9C).	   STS26T	  were	   significantly	  higher	  
than	   all	   other	   cell	   types.	   NHSC,	   ST88-­‐14,	   90-­‐8,	   and	   S462	   lines	   do	   not	   have	  
significantly	  different	  ATP	  production.	  NF1-­‐deficient	  MPNST	  lines	  experience	  lower	  
mitochondrial	  ATP	  Production	  OCR	  compared	  to	  NF1-­‐wildtype.	  	  
Maximal	   Respiration	   OCR	   (Figure	   9D)	   describes	   the	   fastest	   mitochondrial	  
respiratory	   rate	   possible	   and	   indicates	   the	   cellular	   potential	   for	   mitochondrial	  
respiration.	   An	   increased	   Maximal	   Respiration	   may	   result	   from	   increased	  
mitochondrial	   mass,	   increased	   substrate	   availability,	   and	   efficient	   movement	   of	  
electrons	  through	  the	  ETC	  while	  a	  decreased	  Maximal	  Respiration	  may	  result	  from	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decreased	   mitochondrial	   mass,	   decreased	   substrate	   availability,	   and	   impaired	  
electron	   movement	   through	   the	   ETC	   (Hill	   et	   al.,	   2012).	   	   Maximal	   Respiration	   is	  
determined	  using	  FCCP	  and	  Antimycin	  A/Rotenone.	  The	  Maximal	  Respiration	  OCR	  
(mean	  ±	  SEM)	  in	  fmol	  O2/min/cell	  are:	  3.9	  ±	  0.4	  for	  NHSC,	  41	  ±	  2	  for	  STS26T,	  13	  ±	  1	  
for	  ST88-­‐14,	  6.9	  ±	  0.6	  for	  90-­‐8,	  and	  10	  ±	  1	  for	  S462	  (Figure	  9D).	  The	  NF1-­‐wildype,	  
STS26T,	  has	  significantly	  higher	  Maximal	  Respiration	  OCR	  than	  all	  other	  cells	  types.	  
NHSC	   are	   significantly	   lower	   than	   STS26T,	   ST88-­‐14,	   and	   S462.	   The	   NF1-­‐deficient	  
MPNST	  lines	  are	  not	  significantly	  different	  from	  each	  other	  but	  are	  significantly	  less	  
than	  STS26T.	  
Spare	   Respiratory	   Capacity	   OCR	   (Figure	   9E)	   reports	   how	   efficacious	   cells	  
could	   be	   at	  mitigating	   energy	   crises	   via	  mitochondrial	   respiration.	   Cell	   lines	  with	  
high	  Spare	  Respiratory	  Capacities	  may	  easily	  increase	  respiration	  to	  compensate	  for	  
increased	   energy	   demand.	   Spare	   Respiratory	   Capacity	   OCR	   were	   identified	   using	  
FCCP	   and	   Antimycin	   A/Rotenone.	   The	   Spare	   Respiratory	   Capacity	   OCR	   (mean	   ±	  
SEM)	  in	  fmol	  O2/min/cell	  are:	  1.9	  ±	  0.4	  for	  NHSC,	  25	  ±	  2	  for	  STS26T,	  8	  ±	  1	  for	  ST88-­‐
14,	  3.1	  ±	  0.8	  for	  90-­‐8,	  and	  6	  ±	  1	  for	  S462	  (Figure	  9E).	  All	  MPNST	  Spare	  Respiratory	  
Capacities	  are	  higher	  than	  NHSC	  with	  only	  STS26T	  and	  ST88-­‐14	  being	  significantly	  
so.	   STS26T	   was	   significantly	   higher	   than	   NF1-­‐deficient	   MPNST	   and	   NHSC.	   NF1-­‐







NF1-­‐deficient	   MPNST	   have	   lower	   mitochondrial	   respiration	   than	   NF1-­‐
wildtype	  
(A)	  Representative	  depiction	  of	  a	  Mitochondria	  Stress	  Test	  	  (B)	  Mitochondria	  Stress	  
Test	   output	   for	   NHSC	   and	  MPNST	   lines	   (C)	   ATP	   Production	   oxygen	   consumption	  
rates	  for	  NHSC	  and	  MPNST	  lines.	  (D)	  Maximal	  oxygen	  consumption	  rates	  for	  NHSC	  
and	  MPNST	  lines	  (E)	  Spare	  Respiratory	  Capacities.	  Results	  are	  mean	  ±	  SEM.	  n	  =	  5-­‐
10.	  P	  values	  determined	  by	  one-­‐way	  ANOVA	  with	  Tukey	  post	  hoc.	  Oligomycin	  (A)	  =	  
inhibits	   ATP	   synthase,	   FCCP	   =	   dissipates	   the	   electrochemical	   proton	   gradient,	  






















NF1-­‐DEFICIENT	  MPNST	  LINES	  ARE	  LESS	  METABOLIC	  THAN	  NF1-­‐WILDTYPE	  
Basal	  Respiration	  (Figure	  9B)	   is	   the	  rate	  of	  oxygen	  consumed	  at	   rest.	  Basal	  
Respiration,	  in	  a	  tumor	  model,	  has	  important	  implications	  in	  explaining	  the	  energy	  
production	   capabilities	   of	   genetically	   dissimilar	   cells	   concerning	   temporal	   and	  
spatial	  differences	  within	  a	  tumor	  microenvironment.	  Increased	  respiration	  may	  be	  
the	  result	  of	  increased	  ATP	  turnover	  or	  proton	  leak.	  While	  decreased	  respiration	  is	  
caused	   by	   decreased	   ATP	   demand,	   proton	   leak,	   substrate	   supply	   or	   inhibition	   of	  
Complexes	   I-­‐V.	   Antimycin	   A/Rotenone	   were	   used	   to	   test	   Basal	   Respiration.	   The	  
Basal	  Respiration	  OCR	  (mean	  ±	  SEM)	  in	  fmol	  O2/min/cell	  are:	  2.0	  ±	  0.3	  for	  NHSC,	  17	  
±	  1	  for	  STS26T,	  4.9	  ±	  0.5	  for	  ST88-­‐14,	  3.8	  ±	  0.5	  for	  90-­‐8,	  4.7	  ±	  0.5	  for	  S462	  (Figure	  
9B).	   STS26T	   was	   significantly	   higher	   than	   NHSC	   and	   NF1-­‐deficient	   MPNST	   lines.	  
NF1-­‐deficient	  MPNST	  Basal	  Respirations	  were	  not	  significantly	  different	  from	  NHSC.	  	  
A	   metabolic	   profile	   aggregate,	   termed	   PhenoGram	   (Figure	   10B)	   illustrates	  
the	  metabolic	  differences	  between	  NF1-­‐wildtype	  and	  NF1-­‐deficient	  MPNST	  lines.	  All	  
of	   the	   MPNST	   lines	   are	   shifted	   to	   the	   right	   of	   NHSC	   indicating	   a	   higher	   basal	  
glycolysis	  than	  the	  NHSC.	  The	  Glycolysis	  ECAR	  (mean	  ±	  SEM)	  in	  µpH/min/cell	  are:	  
0.14	  ±	  0.02	  for	  NHSC,	  0.77	  ±	  0.07	  for	  STS26T,	  0.24	  ±	  0.01	  for	  ST88-­‐14,	  0.30	  ±	  0.03	  
for	  90-­‐8,	  0.62	  ±	  0.02	  for	  S462	  (Figure	  8C).	  The	  NF1-­‐deficient	  MPNST	  cell	  lines	  have	  
lower	  Basal	  Respiration	   than	   STS26T	  and	   are	   the	   same	  as	  NHSC	   (Figure	  9B).	  The	  






FIGURE	  10	  	  
NF1-­‐deficient	  MPNST	  lines	  are	  less	  metabolic	  than	  NF1-­‐wildtype	  	  
Glycolytic	  and	  Basal	  Respiratory	  Rates	  plotted	  on	  the	  x-­‐	  and	  y-­‐	  axis,	  respectively.	  (A)	  
Representative	  PhenoGram	  depicting	  metabolic	  shift	  to	  a	  more	  glycolytic	  state.	  (B)	  
NHSC	  and	  MPNST	  PhenoGram.	  Note	  that	  NF1-­‐deficient	  MPNST	  lines	  (surrounded	  in	  



































DIFFERENTIAL	   MPNST	   CELL	   LINE	   ELECTRON	   TRANSPORT	   CHAIN	   PROTEIN	  
EXPRESSION	  	  
Western	   Blotting	   was	   used	   to	   determine	   whether	   the	   differences	   in	  
mitochondria	  respiration	  were	  due	  to	  protein	  expression	  (Figure	  11B).	  STS26T	  was	  
the	   only	   cell	   line	   to	   have	   comparable	   or	   increased	   expression	   of	   all	   electron	  
transport	  chain	  complexes	  compared	  to	  NHSC.	  The	  NF1-­‐deficient	  MPNST	  cell	   lines	  
have	  decreased	  expression	  of	  at	   least	  one	  respiratory	  complex	  compared	  to	  NHSC.	  
Complex	   I	   subunit	  NDUFB8	  was	  0.3	   fold	   lower	   than	  NHSC.	  Cytochrome	  C	  was	  0.2	  
fold	  lower	  than	  NHSC	  in	  ST88-­‐14	  and	  0.1	  fold	  lower	  in	  S462.	  Complex	  IV	  subunit	  IV	  
was	  0.4	  fold	  lower	  in	  90-­‐8	  compared	  to	  NHSC.	  Complex	  V	  subunit	  alpha	  was	  0.1	  fold	  
lower	  in	  STS26T,	  0.7	  fold	  lower	  in	  ST88-­‐14,	  0.2	  fold	  lower	  in	  90-­‐8,	  and	  0.4	  fold	  lower	  
in	   S462	   compared	   to	   NHSC.	   	   All	   NF1-­‐deficient	   MPNST	   cell	   lines	   had	   lower	  
mitochondrial	   protein	   expression	   than	  NF1-­‐wildtype	  MPNST.	   Protein	   loading	  was	  
equal	   as	   illustrated	   by	   β-­‐actin.	   Quantitation	   was	   relative	   to	   NHSC.	   Western	   blots	  










FIGURE	  11	  	  
Differential	  expression	  of	  Mitochondrial	  Respiratory	  Proteins	  in	  MPNST	  	  
(A)	  Illustration	  of	  the	  ETC	  with	  election	  and	  proton	  flow	  (B)	  Western	  Blot	  analysis	  of	  
ETC	   Complex	   protein	   expression.	   Quantitation	   relative	   to	   NHSC.	   Western	   blots	  
shown	  are	  representative	  of	  at	   least	  two	  independent	  experiments.	  ETC	  =	  electron	  
transport	   chain,	   Complex	   I	   =	   NADH	   dehydrogenase,	   Complex	   II	   =	   succinate	  
dehydrogenase,	   Q	   =	   coenzyme	   Q,	   Complex	   III	   =	   coenzyme	   Q-­‐cytochrome	   C	  


























NF1-­‐DEFICIENT	  MPNST	  HAVE	  DECREASED	  UNCOUPLING	  
Proton	  Leak	  OCR	  (Figure	  12C)	  is	  the	  rate	  of	  oxygen	  consumed	  by	  the	  electron	  
transport	  chain	  to	  produce	  the	  proton	  gradient	  lost	  via	  proton	  leak.	  Proton	  leak	  via	  
mitochondrial	   uncoupling	  proteins	   (UCP)	  has	   a	   regulatory	   role	   in	  ROS	  production	  
and	  oxidative	  stress	  by	  acting	  as	  a	  throttle	  for	  the	  electron	  transport	  chain	  and	  ATP	  
synthase	   (Jastroch	   et	   al.,	   2010).	   Proton	   Leak	   may	   be	   increased	   in	   response	   to:	  
damaged	   electron	   transport	   chain	   (ETC)	   proteins,	   damaged	   inner-­‐membrane,	  
electron	  slip,	  and	  increased	  uncoupling	  protein	  activity	  (Hill	  et	  al.,	  2012).	  Decreased	  
UCP	  activity	  and	  a	   robust	  ETC	  and	   inner-­‐membrane	  results	   in	  a	  decreased	  Proton	  
Leak.	  	  The	  Proton	  Leak	  OCR	  (mean	  ±	  SEM)	  in	  fmol	  O2/min/cell	  are:	  0.30	  ±	  0.05	  for	  
NHSC,	  3.1	  ±	  0.4	  for	  STS26T,	  1.6	  ±	  0.2	  for	  ST88-­‐14,	  0.2	  ±	  0.2	  for	  90-­‐8,	  and	  1.0	  ±	  0.2	  for	  
S462.	   STS26T	   was	   significantly	   higher	   than	   all	   other	   cell	   lines.	   ST88-­‐14	   was	  
significantly	  different	   from	  NHSC,	  STS26T,	  and	  90-­‐8.	  S462	  was	  significantly	  higher	  
than	  NHSC	  and	  90-­‐8.	  	  
Western	  Blotting	  was	  used	   to	  determine	  whether	   the	  differences	   in	  proton	  
leak	   were	   due	   to	   protein	   expression	   (Figure	   12B).	   STS26T	   had	   the	   highest	  
expression	  levels	  of	  UCP2	  followed	  by	  ST88-­‐14,	  then	  NHSC	  and	  90-­‐8.	  S462	  had	  the	  
lowest	   expression	  of	  UCP2.	  UCP2	  expression	   closely	  mirrored	  proton	   leak	  activity	  
measured	  by	  Extracellular	  Flux	  analysis	  (Figure	  12C).	  Protein	  loading	  was	  equal	  as	  
illustrated	  by	  β-­‐actin.	  Quantitation	  was	  relative	  to	  NHSC.	  Western	  blots	  shown	  are	  




NF1-­‐deficient	  MPNST	  lines	  have	  decreased	  Proton	  Leak	  	  
(A)	  ETC	  illustration	  with	  UCP.	  (B)	  Western	  Blot	  analysis	  of	  UCP2	  protein	  expression.	  
Quantitation	   relative	   to	  NHSC.	  Western	  blots	   shown	  are	   representative	   of	   at	   least	  
two	   independent	   experiments.	   (C)	   NHSC	   and	   MPNST	   Proton	   Leak	   oxygen	  
consumption	  rates.	  Results	  are	  mean	  ±	  SEM.	  n=5-­‐10.	  P	  values	  determined	  by	  one-­‐

































MPNST	  CELL	  LINE	  ROS	  ORIGINATE	  FROM	  MITOCHONDRIA	  	  
Extra-­‐mitochondrial	   sources	   of	   ROS	   like	   nitric	   oxide	   synthase,	   xanthine	  
oxidase,	  and	  lipoxygenase	  consume	  oxygen	  to	  produce	  reactive	  oxygen	  species	  (Hill	  
et	  al.,	  2012).	  ROS	  are	  capable	  of	  damaging	  DNA	  and	  proteins,	  and	  create	  havoc	  by	  
disrupting	   intercellular	   signaling.	  Dichlorofluorescin	   (DCF)	   fluorescence	  measured	  
ROS	   levels	   to	   further	   characterize	   the	   apparent	   respiratory	   dysfunction	   (Figure	  
13B).	  The	  fold	  change	  in	  ROS	  from	  NHSC	  (mean	  ±	  SEM)	  are:	  1.0	  ±	  0.1	  for	  NHSC,	  4.8	  ±	  
0.3	   for	   STS26T,	   2.7	   ±	   0.1	   for	   ST88-­‐14,	   3.2	   ±	   0.2	   for	   90-­‐8,	   and	   1.7	   ±	   0.1	   for	   S462.	  
STS26T	  was	  significantly	  higher	  than	  all	  other	  cells	  types.	  ST88-­‐14,	  90-­‐8,	  and	  S462	  
were	  all	  significantly	  different	  from	  each	  other	  and	  higher	  than	  NHSC.	  
Non-­‐mitochondrial	   Respiration	   OCR	   (Figure	   13C)	   is	   the	   rate	   of	   oxygen	  
consumed	   to	   fuel	   other	   oxygen	   utilizing	   processes.	   Increased	   Non-­‐mitochondrial	  
OCR	  may	  indicate	  increased	  ROS	  production	  through	  extra-­‐mitochondrial	  enzymes	  
(like	  nitric	   oxide	   synthases)	  while	   lower	  Non-­‐mitochondria-­‐derived	  OCR	   indicates	  
decreased	  non-­‐mitochondrial	  ROS	  production.	  Antimycin	  A/Rotenone	  were	  used	  to	  
determine	   Non-­‐mitochondria	   OCR.	   The	   Non-­‐mitochondria-­‐derived	   OCR	   (mean	   ±	  
SEM)	  in	  fmol	  O2/min/cell	  are:	  0.56	  ±	  0.02	  for	  NHSC,	  1.7	  ±	  0.2	  for	  STS26T,	  1.0	  ±	  0.1	  
for	  ST88-­‐14,	  1.1	  ±	  0.1	  for	  90-­‐8,	  and	  0.9	  ±	  0.1	  for	  S462.	  STS26T	  is	  significantly	  higher	  
than	  all	  other	   cell	   lines	  apart	   from	  90-­‐8.	  The	  NF1-­‐deficient	  MPNST	  cell	   lines	  were	  
not	  significantly	  different	  from	  each	  other	  or	  NHSC.	  Nitric	  oxide	  synthase	  (NOS)	  is	  a	  
possible	  source	  of	  non-­‐mitochondrial	  oxygen	  consumption	  (Figure	  13D).	  eNOS	  and	  
nNOS	  protein	  expression	  was	  evaluated	  by	  Western	  blot	  analysis.	  eNOS	  expression	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was	  found	  to	  be	  lower	  in	  MPNST	  cell	  lines	  than	  NHSC	  and	  nNOS	  expression	  was	  also	  























FIGURE	  13	  	  
MPNST	  cell	  line	  ROS	  originate	  from	  mitochondria	  	  
(A)	  Schematic	  detailing	  mitochondrial	  production	  of	  ROS.	  (B)	  ROS	  levels	  as	  fold	  
change	  from	  NHSC.	  n=8.	  (C)	  Non-­‐mitochondrial	  oxygen	  consumption	  rates.	  n=5-­‐10.	  	  
Results	  are	  mean	  ±	  SEM.	  P	  values	  determined	  by	  one-­‐way	  ANOVA	  with	  Tukey	  post	  
hoc	  (D)	  Western	  blot	  analysis	  of	  eNOS	  and	  nNOS	  expression.	  Quantitation	  relative	  to	  
NHSC.	  Even	  protein	  loading	  determined	  by	  β-­‐actin	  expression.	  Western	  blots	  shown	  
are	  representative	  of	  at	  least	  two	  independent	  experiments.	  eNOS	  =	  endothelial	  








































































Similar	  to	  other	  tumors	  and	  tumor	  cell	  lines,	  the	  MPNST	  cell	  lines	  examined	  
in	   this	   study	   exhibited	   the	   increased	   glycolytic	   rates	   noted	   in	   the	  Warburg	   effect	  
when	   compared	   to	   a	   non-­‐tumorigenic	  NHSC	   line.	   One	   explanation	   for	   this	   change	  
may	   be	   because	   glycolysis	   produces	   ATP	   faster	   than	   oxidative	   phosphorylation.	  
Tumor	   cells	  may	   shift	   to	   a	  more	   glycolytic	   state	   in	   order	   to	  maintain	   the	   energy	  
requirements	  necessary	  for	  sustained	  elevation	  of	  cellular	  proliferation	  –	  especially	  
in	   a	   nutrient-­‐deprived,	   hypoxic	   environment.	   Testing	   whether	   a	   hypoxic	  
environment	  would	  cause	  this	  switch	  in	  our	  cells	  was	  not	  performed,	  but	  is	  possible	  
to	  do	  in	  our	  system	  using	  a	  hypoxia	  chamber	  and	  varying	  nutrient	  concentrations	  in	  
cellular	  media.	  Our	   findings	   that	   all	   tumor	   lines	  had	   faster	   glycolysis	   than	  normal	  
Schwann	   cells	   are	   consistent	   with	   the	   notion	   that	   the	   tumor	   lines	   have	   higher	  
growth	  rate	  and	  energy	  demands.	  
Hyperactivation	   of	   the	   Ras	   pathway	   has	   been	   found	   in	  many	   tumor	   types;	  
therefore,	  it	  is	  interesting	  that	  patients	  with	  Neurofibromatosis	  Type	  I	  have	  a	  higher	  
incidence	  of	  MPNST.	  Patients	  with	  NF1	  have	  a	  genetic	  mutation	  or	  loss	  of	  function	  of	  
the	  NF1	  gene,	  encoding	  the	  neurofibromin	  protein.	  Since	  NF1	  is	  a	  Ras-­‐GTPase,	  it	  acts	  
to	  turn	  the	  Ras	  pathway	  off.	  NF1-­‐deficient	  cells	  have	  increased	  Ras-­‐MAPK	  signaling.	  	  
Previous	   reports	   have	   linked	   Ras	   hyperactivation	   to	   an	   increase	   in	   glycolysis	   in	  
embryonic	  fibroblasts	  (de	  Groof	  et	  al.,	  2009).	  Our	  findings	  that	  Nf1-­‐deficient	  MPNST	  
cell	  lines	  have	  lower	  glycolytic	  rates	  compared	  to	  an	  NF1-­‐wildtype	  MPNST	  cell	  line	  
diverges	  with	  previous	  studies	  involving	  the	  Ras	  pathway	  in	  non-­‐tumorigenic	  cells	  
suggesting	  that	  the	  loss	  of	  NF1/hyperactivation	  of	  Ras	  may	  decrease	  glycolytic	  rates	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in	   MPNST.	   All	   MPNST	   cell	   lines	   did	   have	   higher	   glycolytic	   rates	   than	   normal	  
Schwann	  cells.	  
The	  role	  of	  Ras	  on	  mitochondrial	  respiration	  has	  been	  controversial,	  but	  the	  
consensus	  seems	  to	  be	  that	  Ras	  hyperactivation	  results	  in	  decreased	  mitochondrial	  
respiration	   (Telang	  et	   al.,	   2007,	  de	  Groof	  et	   al.,	   2009,	  Yang	  and	  Wang	  et	   al.,	   2010,	  
and	  Hu,	  Lu	  and	  Chen	  et	  al.,	  2012).	  Conclusions	  made	  from	  the	  Hu,	  Lu,	  and	  Chen	  et	  al.,	  
2012	   article	   should	   be	   made	   cautiously	   as	   doxycycline	   was	   used	   to	   induce	   Ras	  
hyperactivation	  and	  the	  tetracycline	  family	  of	  antibiotics,	  of	  which	  doxycycline	  is	  a	  
member,	   are	   known	   to	   directly	   decrease	   proliferation	   and	   shift	   metabolism	   to	   a	  
more	   glycolytic	   phenotype	  while	   decreasing	  mitochondrial	   respiration	   (Ahler	   and	  
Sullivan	  et	  al.,	  2012).	  Wang	  and	  Song	  recently	  identified	  that	  K-­‐Ras	  hyperactivation	  
caused	   mitochondrial	   dysfunction	   by	   decreasing	   NADH	   dehydrogenase	   1	   alpha	  
subcomplex	  assembly	  factor	  1	  (NDUFAF1)	  expression	  	  (Wang	  and	  Song	  et	  al.,	  2015).	  
NDUFAF1	   is	   a	   protein	   involved	   in	   the	   assembly	   of	   Complex	   1.	  Other	   studies	   have	  
demonstrated	   a	   decrease	   in	   Complex	   1	   activity	   upon	   Ras	   transformation	   that	   is	  
connected	   with	   the	   mitochondrial	   respiratory	   depression	   (Baracca	   et	   al.,	   2010).	  
Further	  research	  is	  needed	  to	  determine	  the	  extent	  of	  Ras	  impact	  on	  mitochondria.	  	  
Several	   studies	   have	   evaluated	   the	   effect	   of	   Ras	   hyperactivation	   on	  
mitochondrial	   respiration	   but	   not	   as	   many	   studies	   have	   been	   done	   to	   determine	  
whether	   Ras	   directly	   effects	   glycolysis.	   One	   of	   the	   few	   studies	   found	   that	   Ras-­‐
induced	  changes	  in	  glycolysis	  are	  regulated	  by	  6-­‐Phosphofructo-­‐2-­‐Kinase/Fructose-­‐
2,6-­‐Bisphosphatase	   3	   (PFKFB3)	   activity	   in	   murine	   lung	   fibroblasts	   (Telang	   et	   al.,	  
2009).	   PFKB3	   increased	   fructose	   2,6-­‐biphosphate	   (F-­‐2,6-­‐BP)	   levels	   upon	   Ras	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hyperactivation.	   F-­‐2,6-­‐BP	   increases	   glycolysis	   through	   allosteric	   activation	  
phosphofructokinase-­‐1	   (PFK-­‐1)	   by	   increasing	   PFK-­‐1	   affinity	   for	   fructose	   6-­‐
phosphate	   and	  decreasing	   its	   affinity	   for	   the	   allosteric	   inhibitors,	  ATP	  and	   citrate.	  	  
PFK-­‐1	  is	  a	  crucial	  regulatory	  step	  in	  glycolysis.	  	  Given	  these	  findings,	  it	  is	  reasonable	  
to	  hypothesize	  that	  F	  2,6-­‐BP	  is	  increased	  in	  the	  MPNST	  cell	  lines	  derived	  from	  NF1	  
patients	  and	  assists	  in	  generation	  of	  the	  increased	  glycolytic	  state	  observed.	  	  Future	  
experiments	  may	  examine	  this	  point.	  
The	   finding	   that	   NF1-­‐deficient	   MPNST	   cell	   lines	   have	   significantly	   lower	  
glycolysis	   than	   that	   found	   in	   the	  NF1-­‐expressing	  MPNST	   line	  was	  surprising.	  NF1-­‐
deficient	  MPNST	  cell	  lines	  were	  also	  significantly	  less	  metabolic	  with	  lower	  oxygen	  
consumption	  rates,	  maximal	   respiration,	  and	  spare	  respiratory	  capacity	   than	  NF1-­‐
wildtype,	   indicating	   the	   capability	   of	   NF1-­‐deficient	   tumor	   cell	   lines	   to	   produce	  
energy	   via	   oxidative	   phosphorylation	   is	   considerably	   lower	   than	   NF1-­‐wildtype	  
malignant	  cells.	  	  
When	   we	   compared	   the	   various	   NF1-­‐deficient	   MPNST	   cell	   lines	   to	   one	  
another,	   they	   all	   responded	   in	   a	   similar	   manner	   to	   metabolic	   stress,	   with	   more	  
variability	   noted	   in	   glycolytic	   rates	   than	   overall	   metabolism.	   Increases	   in	   both	  
glycolytic	   and	   mitochondrial	   respiration	   indicate	   more	   energetic	   cells	   when	  
compared	   to	   wildtype,	   non-­‐tumorigenic	   NHSC.	   The	   variability	   between	   the	   NF1-­‐
deficient	  MPNST	   lines	   examined	   in	   this	   study	  was	   substantial,	  with	  more	   striking	  
differences	   shown	   between	   the	   NF1-­‐deficient	   ST88-­‐14	   line	   and	   the	   NF1-­‐wildtype	  
STS26T	  cell	  line	  which	  are	  historically	  the	  most	  commonly	  compared	  lines	  for	  NF1	  
loss	  changes.	  	  
	  75	  
All	  of	   the	  MPNST	  cell	   lines	  (regardless	  of	  NF1	  status)	  have	  multiple	  genetic	  
mutations.	  The	  genetic	  mutation(s)	  within	  the	  lines	  examined	  in	  this	  study	  has	  not	  
been	   identified,	   as	   full	   genetic	   sequencing	   has	   not	   been	   preformed.	   Therefore,	  
investigators	  have	  historically	  assumed	  that	  any	  differences	  observed	  between	  NF1-­‐
deficient	  MPNST	  lines	  could	  be	  attributable	  to	  variations	  in	  cell	  line	  history	  and/or	  
genetics.	  Although	  we	  did	  see	  individual	  expression	  differences	  in	  specific	  subunits	  
of	  the	  Complexes	  in	  each	  of	  the	  cell	   lines,	  this	  could	  be	  one	  reason	  that	  we	  did	  not	  
find	   any	   specific	   or	   distinct	   pattern(s)	   in	   respiratory	   protein	   expression	   that	   we	  
think	   could	   fully	   explain	   the	   metabolic	   activity	   measurements	   obtained	   through	  
Extracellular	   Flux	   analysis.	   Furthermore,	   these	   mitochondrial	   complexes	   are	  
composed	   of	   a	   multitude	   of	   subunits	   that	   could	   not	   be	   segregated	   out	   using	   the	  
antibodies	   that	   are	   currently	   available.	   Mass	   spectrometric	   analysis	   of	  
mitochondrial	  respiratory	  complexes	  has	  been	  used	  previously	  and	  may	  provide	  a	  
more	   complete	   accounting	  of	   the	   subunits	   expressed	  and	   in	  what	   ratios	   (Schilling	  
and	  M.	  M.	  et	  al.,	  2005).	  
Previous	   research	   using	   the	   same	   cell	   lines	   used	   in	   this	   study	   and	   other	  
MPNST	  lines	  (both	  NF1-­‐wildtype	  and	  NF1-­‐deficient)	  claim	  that	  NF1	  status	  does	  not	  
have	  an	  impact	  on	  proliferation	  rate	  (Miller	  et	  al.,	  2006).	  This	  article	  used	  an	  MTT	  
assay	   as	   a	  measure	   of	   cellular	   proliferation,	  which	   is	   a	   common	  practice	   in	  many	  
labs.	  However,	   the	  MTT	  assay	   is	  not	   always	   a	   good	   indicator	  of	   proliferation	   as	   it	  
actually	  measures	  NAD(P)H-­‐dependent	   oxidoreductase	   (Complex	   I)	   activity	   in	   the	  
reduction	   of	   MTT	   to	   the	   insoluble	   and	   detectable	   tetrazolium	   dye.	   There	   is	   a	  
correlation	  between	  high	  MTT	  results	  and	  proliferating	  cells	  because	  as	  cells	  divide	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their	   energy	   consumption	   goes	   up.	   However,	   differences	   in	   metabolism	   can	   also	  
alter	   MTT	   without	   a	   change	   in	   proliferation	   rates.	   For	   example,	   if	   cells	   are	   less	  
efficient	  at	  utilizing	  energy,	  then	  a	  higher	  MTT	  will	  result	  –	  especially	  if	  they	  obtain	  
more	   of	   their	   energy	   from	   glycolysis	   and	   not	   mitochondrial	   respiration.	   For	   this	  
reason,	   I	   propose	   that	   both	  MTT	   and	   proliferation	   counts	   be	   performed	   to	  more	  
accurately	   characterize	   how	   NF1	   status	   may	   effect	   proliferation	   rates	   and/or	  
metabolism	  changes	  in	  these	  cell	  lines.	  	  
Proton	   leak	   through	   uncoupling	   proteins	   (UCP)	   acts	   as	   a	   throttle	   for	  
mitochondrial	  respiration.	  We	  found	  that	  NF1-­‐deficient	  MPNST	  have	  lower	  rates	  of	  
proton	  leak	  than	  the	  NF1-­‐wildtype	  MPNST	  cell	  line	  and	  proton	  leak	  activity	  closely	  
mirrors	   UCP2	   expression	  with	   the	   exception	   of	   S462.	   The	   observation	   that	   UCP2	  
expression	  does	  not	  reflect	  proton	  leak	  in	  S462	  could	  be	  due	  to:	  the	  S462	  line	  may	  
express	  a	  different	  uncoupling	  protein	  or	  UCP2	  in	  S462	  may	  undergo	  different	  post-­‐
translational	  modifications	  that	  alter	  the	  size	  of	  the	  protein	  and	  change	  its	  location	  
on	   the	   western	   blot	   membrane.	   Proton	   leak	   can	   be	   changed	   by	   multiple	   factors	  
beyond	   UCP	   protein	   expression	   –	   such	   as	   damage	   to	   the	   membrane	   or	   electron	  
transport	   chain	   protein(s).	   Therefore,	   while	   the	   proton	   leak	   we	   noted	   in	   the	  
extracellular	   flux	   data	   correspond	   nicely	  with	  UCP	   expression	   data,	   it	   is	   probable	  
that	   other	   factors	   also	   play	   a	   role.	   Superoxide	   (a	   reactive	   oxygen	   species)	  
production	   is	   responsive	   to	   changes	   in	   the	   proton-­‐motive	   force	   via	   uncoupling	  
proteins	   (Jastroch	   et	   al.,	   2010).	   The	   decreased	   activity	   and	   expression	   of	  UCP2	   in	  
NF1-­‐deficient	   MPNST	   compared	   to	   NF1-­‐wildtype	   MPNST	   indicates	   decreased	  
electron	  transport	  chain	  control	  and	  highlights	  the	  possibility	  of	  increased	  reactive	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oxygen	   species	   (ROS)	   production	   in	   NF1-­‐deficient	   MPNST	   cells	   compared	   to	  
wildtype	  MPNST.	  Moderate	   uncoupling	   helps	   prevent	   the	   build	   up	   of	   substrate	   at	  
the	   respiratory	   proteins	   and	  may	   decrease	   premature	   electron	   removal	   from	   the	  
transport	  chain	  and	  creation	  of	  reactive	  oxygen	  species.	  	  
Mitochondria	  are	  the	  major	  producer	  of	  cellular	  reactive	  oxygen	  species.	  ROS	  
are	  an	  unavoidable	  byproduct	  of	  mitochondrial	   respiration	  and	   increased	  ROS	  are	  
routinely	   observed	   in	   cancer	   cells.	   ROS	   are	   implicated	   in	   tumor	   progression	   and	  
persistence	   of	   the	  malignant	   state	   through	   activation	   of	   transcription	   factors	   like	  
HIF-­‐1α	   and	   FOS-­‐JUN	   that	   will	   modify	   protein	   expression	   and	   promote	   cell	  
proliferation	   (Wallace	   2012).	   ROS	   can	   further	   exacerbate	   tumorgenicity	   by	  
activating	  ERK1/2,	  a	  member	  of	  the	  MAPK	  pathway	  downstream	  of	  Ras	  (Weinberg	  
et	  al.,	  2010).	  ROS	  are	   involved	  in	  NF1	  behavioral	  deficits	  (Mayes	  et	  al.,	  2013).	  ROS	  
levels	  were	   examined	  using	   CM-­‐H2DCFDA—a	  general	   indicator	   of	   oxidative	   stress	  
(Kuznetsov	  et	  al.,	  2011).	  DCF,	  the	  fluorescent	  product,	  responds	  to	  superoxide,	  nitric	  
oxide,	  and	  peroxynitrite,	  among	  several	  other	  reactive	  oxygen	  species.	  MPNST	  have	  
higher	  ROS	  relative	  to	  NHSC	  with	  NF1-­‐deficient	  having	  significantly	  lower	  levels	  of	  
ROS	  than	  NF1-­‐wildtype	  MPNST.	  	  
The	   increased	  ROS	  observed	   in	   the	  NF1-­‐deficient	  MPNST	  cells	  compared	  to	  
NHSC	   originate	   from	   the	   mitochondria	   because	   the	   NF1-­‐deficient	   MPNST	   Non-­‐
mitochondrial	  oxygen	  consumption	  rates	  are	  not	  significantly	  different	  from	  NHSC,	  
meaning	   that	   the	   other	   processes	   within	   the	   cells	   that	   utilize	   oxygen	   are	   not	  
consuming	   oxygen	   at	   different	   rates.	   The	   NF1-­‐wildtype	   MPNST	   cell	   line	   has	  
significantly	   higher	   Non-­‐mitochondrial	   respiration	   from	   two	   of	   the	   NF1-­‐deficient	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lines	   and	   NHSC,	   indicating	   that	   the	   NF1-­‐wildtype	  MPNST	   cells	   have	   an	   increased	  
oxygen	   utilization	   for	   processes	   other	   than	   respiration.	   NF1-­‐wildtype	   is	   not	  
different	  from	  one	  of	  the	  NF1-­‐deficient	  cell	  lines.	  	  
Nitric	  oxide	  synthase	  had	  previously	  been	  shown	  culpable	  in	  the	  generation	  
of	  NF1-­‐cognitive	  and	  behavioral	  phenotypes.	  NOS	  produces	  nitric	  oxide	  (NO)	  which	  
is	  a	  ROS.	  NOS	  protein	  expression	  levels	  were	  examined	  using	  Western	  blot	  analysis;	  
however,	  no	  specific	  trends	  were	  noted	  between	  the	  lines.	  	  Most	  of	  the	  lines	  did	  not	  
express	  eNOS	  and	  nNOS	   isoforms	  while	  NHSC	  did.	  The	   increased	  ROS	  observed	   in	  
NF1-­‐deficient	  could	  be	  a	  result	  of	  electron	  transport	  chain	  damage	  due	  to	  mutations	  
or	   other	   mitochondrial	   dysfunction.	   	   An	   alternate	   possibility	   is	   that	   there	   is	   a	  
reduction	  in	  ROS	  scavenging	  by	  superoxide	  dismutase	  2	  (SOD2).	  	  	  
The	   final	  point	   is	  perhaps	   the	  most	   tenuous.	  The	  NF1-­‐wildtype	  MPNST	  cell	  
line	   (ST26T)	   had	   significantly	   higher	   mitochondrial	   respiration	   than	   NHSC,	   more	  
than	   8	   times	   higher	  while	   producing	   5	   times	   as	  much	   ROS.	  While	   in	   contrast	   the	  
NF1-­‐deficient	  MPNST	  lines	  had	  about	  2	  times	  faster	  mitochondrial	  respiration	  (not	  
significantly	  different)	  and	  produce	  about	  3	  times	  as	  much	  ROS.	  Together	  these	  data	  
suggest	   that	   the	  MPNST	   lines	  derived	   from	  NF1	  patients	  are	  producing	  more	  ROS	  
for	  their	  respiratory	  rate	  than	  the	  wildtype	  MPNST	  line,	  perhaps	  indicating	  a	  higher	  
degree	   of	   mitochondrial	   dysfunction	   in	   the	   Ras	   transformed	   tumor	   cells	   than	  
sporadic	  tumor	  cells.	  	  
In	  summary,	  we	  found	  significant	  differences	  in	  glycolysis	  and	  mitochondrial	  
respiratory	   rates	   and	   respiratory	   protein	   expression	   between	   NF1-­‐wildtype	   and	  
NF1-­‐deficient	  MPNST	  cells.	  These	  differences	  alter	  the	  way	  the	  cells	  produce	  energy	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and	   mitigate	   energy	   crises.	   The	   mitochondrial	   respiratory	   dysfunction	   influences	  
proliferation	  and	  ROS	  generation.	  The	  observations	  described	  in	  this	  thesis	  should	  
increase	   the	  caution	  of	  researchers	  using	   these	  MPNST	  cell	   lines,	  as	   they	  highlight	  
the	   fact	   that	   each	  MPNST	   have	   fundamentally	   different	   metabolic	   profiles,	   which	  





















To	   strengthen	   the	   findings	   that	   NF1-­‐deficient	   MPNST	   cell	   lines	   have	  
decreased	  mitochondrial	   respiration	   and	   to	   suggest	   an	   explanation	   as	   to	  why	   the	  
cell	  lines	  behave	  the	  ways	  they	  do,	  several	  more	  experiments	  should	  be	  done.	  	  	  
Probing	   the	   MPNST	   cell	   lines	   for	   the	   expression	   of	   S100	   protein	   using	  
immunocytochemistry	  will	  indicate	  how	  similar	  MPNST	  cells	  are	  to	  NHSC.	  S100	  is	  a	  
family	  of	  proteins	  expressed	  in	  cells	  derived	  from	  the	  neural	  crest	  and	  is	  used	  as	  a	  
marker	  for	  Schwann	  cells.	  If	  MPNST	  cell	   lines	  no	  longer	  express	  S100	  then	  the	  cell	  
lines	  have	  degenerated	  far	  from	  what	  their	  cell	  of	  origin	  is	  thought	  to	  be	  and	  caution	  
should	  be	  used	  when	  comparing	  NHSC	  and	  MPNST	  cell	  lines	  as	  NHSC	  may	  no	  longer	  
be	   a	   good	   normal	   control	   cell	   for	  MPNST	   cell	   lines.	   Previous	   research	   claims	   that	  
S100	  is	  not	  expressed	  in	  MPNST	  cell	  lines	  (Miller	  et	  al.,	  2006).	  	  
Another	   experiment	   that	   should	   be	   done	   is	   a	   cell	   proliferation	   assay.	  
Proliferation	  data	  has	  been	  previously	  published	  using	  a	  MTT	  assay.	  In	  light	  of	  the	  
findings	   within	   this	   document	   the	   MTT	   assay	   is	   not	   a	   good	   measure	   of	   cellular	  
proliferation	   because	   the	   MTT	   assay	   is	   thought	   to	   actually	   measure	   NAD(P)H	  
turnover	   at	   NAD(P)H	   oxidoreductases,	   like	   Complex	   I.	   Within	   metabolically	  
remodeled	  cells,	  a	   technique	  based	  on	  the	  measurement	  of	  one	  energy	  production	  
pathway	   and	   interpreted,	   as	   proliferation	   is	   erroneous	   because	  NF1-­‐wildtype	   and	  
NF1-­‐defiecent	  MPNST	  cell	  lines	  have	  drastically	  different	  mitochondrial	  respiration	  
rates.	   Therefore,	   a	   technique	   measuring	   substrate	   turnover	   may	   not	   accurately	  
represent	   proliferative	   rates	   because	   two	   major	   pathways	   of	   energy	   production	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exist.	   A	   series	   of	   direct	   cell	   counts	   over	   several	   days	   should	   provide	   the	   most	  
accurate	  information	  and	  allow	  for	  correlation	  of	  metabolic	  rates	  to	  proliferation.	  	  
The	  last	  experiment	  would	  be	  to	  determine	  the	  mitochondrial	  volume	  for	  the	  
cell	  lines	  via	  immunocytochemistry.	  Mitochondrial	  volume	  can	  serve	  as	  a	  surrogate	  
for	   mitochondria	   amount.	   The	   mitochondrial	   volume	   can	   be	   determined	   using	  
TOM20	  to	  reveal	  mitochondria	  and	  Na+/K+	  ATPase	   to	  show	  the	   total	   cell	  volume.	  
Mitochondrial	  volume	  would	  be	  normalize	   to	  cellular	  volume.	   If	   the	  mitochondrial	  
volume	  was	  the	  same	  for	  all	  lines	  then	  the	  differences	  in	  mitochondrial	  respiration	  
would	   be	   a	   result	   of	   activity	   regulation	   and	   some	   protein	   expression.	   While	   if	  
significant	  differences	  were	  found	  between	  the	  sporadic	  MPNST	  and	  NF1-­‐deficient	  
MPNST	   lines	   then	   it	   would	   be	   indicative	   of	   a	   greater	   systemic	   problem	   such	   as	  
increased	  mitophagy	  or	  mitochondrial	  biogenesis.	  	  
Determing	  whether	  MPNST	  cell	  lines	  derived	  from	  NF1	  patients	  have	  greater	  
mitophagy	   than	   wildtype	   MPNST	   would	   greatly	   influence	   the	   conclusions	   of	   this	  
study.	   	  The	  findings	  of	  the	  experiment	  may	  provide	  evidence	  for	  the	  claim	  that	  the	  
decreased	   mitochondrial	   respiration	   observed	   in	   NF1-­‐deficient	   MPNST	   cell	   lines	  
may	   be	   caused,	   in	   part,	   by	   increased	   mitophagy.	   	   	   Perhaps	   a	   good	   method	   to	  
determine	   amount	   of	   mitophagy	   in	   a	   given	   cell	   would	   be	   to	   measure	   the	  
colocalization	  of	  TOM20	  and	  LC3B	  proteins	  using	  immunofluorescence	  microscopy.	  
TOM20	   is	   found	   on	   mitochondrial	   membranes	   and	   is	   used	   to	   translocate	  
mitochondria	  proteins	  to	  mitochondrial	  membranes.	  LC3B	  is	  involved	  in	  formation	  
of	   autophagosomes	   and	   is	   used	   as	   a	   marker	   for	   autophagic	   membranes.	  
Autophagosomes	  traffic	  cellular	  components	  to	  lysosomes	  for	  degradation.	  The	  two	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proteins	   would	   be	   probed	   with	   different	   fluorescent	   probes	   and	   then	   imaging	  
software	  would	  calculate	  the	  amount	  of	  overlap	  the	  two	  different	  wavelengths	  have	  
within	   a	   single	   pixel	   and	   produce	   a	   colocalization	   value.	   A	   higher	   value	   of	  
colocalization	   indicates	   that	   there	   is	   a	   greater	   amount	   of	   overlap	   between	  
mitochondria	   and	   autophagosome	   membranes	   meaning	   a	   higher	   amount	   of	  
mitophagy.	   If	   the	   levels	  of	  mitophagy	   in	  NF1-­‐deficient	  MPNST	  cell	   lines	  are	  higher	  
than	   wildtype	   MPNST	   then	   mitophagy	   may	   be	   contributing	   to	   the	   lower	  
mitochondrial	   respiration	   observed.	   If	   the	   levels	   of	   mitophagy	   are	   not	   different	  
between	   the	   two	   types	   of	   MPNST	   then	   the	   decreased	   mitochondrial	   respiration	  
observed	   is	   probably	   caused	   by	   some	   other	   mechanism	   (for	   example;	   directly	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